Substituted Amino-arylcarboxamides as KCNQ2/3 modulators

The invention relates to substituted amino-arylcarboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

The treatment of pain, in particular of neuropathic pain, is of great importance in medicine. There is a worldwide need for effective pain therapies. The urgent need for action for a target-orientated treatment of chronic and non-chronic states of pain appropriate for the patient, by which is to be understood the successful and satisfactory treatment of pain for the patient, is also documented in the large number of scientific works which have recently been published in the field of applied analgesics and of fundamental research into nociception.

A pathophysiological feature of chronic pain is the overexcitability of neurons. Neuronal excitability is influenced decisively by the activity of K ^* channels, since these determine decisively the resting membrane potential of the cell and therefore the excitability threshold. Heteromeric K ⁺ channels of the molecular subtype KCNQ2/3 (Kv7.2/7.3) are expressed in neurons of various regions of the central (hippocampus, amygdala) and peripheral (dorsal root ganglia) nervous system and regulate the excitability thereof. Activation of KCNQ2/3 K ⁺ channels leads to a hyperpolarization of the cell membrane and, accompanying this, to a decrease in the electrical excitability of these neurons. KCNQ2/3-expressing neurons of the dorsal root ganglia are involved in the transmission of nociceptive stimuli from the periphery into the spinal marrow (Passmore er a/., J. Neurosci. 2003; 23(18): 7227-36).

It has accordingly been possible to detect an analgesic activity in preclinical neuropathy and inflammatory pain models for the KCNQ2/3 agonist retigabine (Blackburn-Munro and Jensen, Eur J Pharmacol. 2003; 460(2-3); 109-16; Dost ef a/., Naunyn Schmiedebergs Arch Pharmacol 2004; 369(4): 382-390).

The KCNQ2/3 K ⁺ channel thus represents a suitable starting point for the treatment of pain; in particular of pain selected from the group consisting of chronic pain, acute pain, neuropathic pain, inflammatory pain, visceral pain and muscular pain (Nielsen er a/., Eur J Pharmacol. 2004; 487(1 -3): 93-103), in particular of neuropathic and inflammatory pain.

Moreover, the KCNQ2/3 K ⁺ channel is a suitable target for therapy of a large number of further diseases, such as, for example, migraine (US2002/0128277), cognitive diseases (Gribkoff, Expert Opin Ther Targets 2003; 7(6): 737-748), anxiety (Korsgaard er a/., J Pharmacol Exp Ther. 2005, 14(1 ): 282-92), epilepsy (Wickenden er a/., Expert Opin Ther Pat 2004; 14(4): 457-469; Gribkoff, Expert Opin Ther Targets 2008, 12(5): 565-81 ; Miceli er a/., Curr Opin Pharmacol 2008, 8(1 ): 65-74), urinary incontinence (Streng er a/., J Urol 2004; 172: 2054-2058), dependency (Hansen er a/., Eur J Pharmacol 2007, 570(1 - 3): 77-88), mania/bipolar disorders (Dencker er a/., Epilepsy Behav 2008, 12(1 ): 49-53) and dystonia- associated dyskinesias (Richter et al., Br J Pharmacol 2006, 149(6): 747-53).

Substituted compounds that have an affinity for the KCNQ2/3 K ⁺ channel are e.g. known from the prior art (WO 2012/052167, WO 2008/046582, WO 2010/046108, WO 2010/102809 and WO 2002/066036).

There is a demand for further compounds having comparable or better properties, not only with regard to affinity to KCNQ2/3 K ⁺ channels per se (potency, efficacy).

Thus, it may be advantageous to improve the metabolic stability, the solubility in aqueous media or the permeability of the compounds. These factors can have a beneficial effect on oral bioavailability or can alter the P /PD (pharmacokinetic/pharmacodynamic) profile; this can lead to a more beneficial period of effectiveness, for example. A weak or non-existent interaction with transporter molecules, which are involved in the ingestion and the excretion of pharmaceutical compositions, is also to be regarded as an indication of improved bioavailability and at most low interactions of pharmaceutical compositions.

Furthermore, the interactions with the enzymes involved in the decomposition and the excretion of pharmaceutical compositions should also be as low as possible, as such test results also suggest that at most low interactions, or no interactions at all, of pharmaceutical compositions are to be expected.

In addition, it may be advantageous if the compounds show a high selectivity towards other receptors of the KCNQ family (specificity), e.g. towards KCNQ1 , KCNQ3/5 or KCNQ4. A high selectivity may have a positive effect on the side effects profile: for example it is known that compounds which (also) have an affinity to KCNQ1 are likely to have a potential for cardial side effects. Therefore, a high selectivity towards KCNQ1 may be desirable. However, it may also be advantageous for the compounds to show a high selectivity towards other receptors. For instance, it may be advantageous for the compounds to show a low affinity for the hERG ion channel or the L-type calcium ion channel (phenylalkylamine-, benzothiazepin-, dihydropyridine-binding site) since these receptors are known to possibly have a potential for cardial side effects. Further, an improved selectivity towards binding to other endogenic proteins (i.e. receptors or enzymes) may result in a better side effects profile and, consequently to an improved tolerance.

It was therefore an object of the invention to provide new compounds having advantages over the compounds of the prior art. These compounds should be suitable in particular as pharmacological active ingredients in pharmaceutical compositions, preferably in pharmaceutical compositions for the treatment and/or prophylaxis of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K ⁺ channels.

That object is achieved by the subject-matter described herein.

It has been found, surprisingly, that compounds of the general formula (I) given below are suitable for the treatment of pain. It has also been found, surprisingly, that substituted compounds of the general formula (I) given below also have an excellent affinity for the KCNQ2/3 K ⁺ channel and are therefore suitable for the prophylaxis and/or treatment of disorders and/or diseases that are mediated at least in part by KCNQ2/3 K ⁺ channels. The substituted compounds thereby act as modulators, i.e. agonists or antagonists, of the KCNQ2/3 K ⁺ channel.

The present invention therefore relates to a compound of general formula (I),

(I),

wherein

A ¹ represents CR ⁵ or N;

A ² represents CR ⁶ , N, O, S or NR ⁷ ;

A ³ represents CR ⁸ or N, and

n denotes 0 or 1 ,

on the condition, that

if n denotes 0, then A ² represents O, S or NR ⁷ , or

if n denotes 1 , then A ² represents CR ⁶ or N,

wherein

R ⁵ is selected from F, CI, Br, CN, CH ₃ , CF ₃ , CHF ₂ , CH ₂ F, OCH ₃ , C ₂ H ₅ , SCH ₃ , OCF ₃ , OCHF ₂ or OCH ₂ F; R ⁶ is selected from H, F, CI, Br, CN, CH ₃ , CF ₃ , CHF ₂ , CH ₂ F, OCH ₃ , C ₂ H ₅ , SCH ₃ , OCF ₃ , OCHF ₂ or OCH ₂ F; R ⁷ represents C^-aliphatic residue or Cj-s-cycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted;

R ⁸ is selected from H, F, CI, Br, CN, CH ₃ , CF ₃ , CHF ₂ , CH ₂ F, OCH ₃ , C ₂ H ₅ , SCH ₃ , OCF ₃ , OCHF ₂ or OCH ₂ F;

with the proviso, that,

if n denotes 1 , then at least one of A ¹ , A ² and A ³ denotes N,

with the proviso, that

if n denotes 1 and A ³ denotes N, then A ¹ and/or A ² denotes N,

and with the proviso, that

if n denotes 1 and A ² denotes N and A ¹ denotes CR ⁵ and A ³ denotes CR ⁸ , then R ⁵ denotes F, CI, CH ₃ , CF ₃ , CHF ₂ or CH ₂ F;

R ¹³ represents H or C^-aliphatic residue,

R ¹ represents

Ci.io-aliphatic residue, unsubstituted or mono- or polysubstituted; or

C ₃ _io-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

or aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C^-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

R ² represents C^e-aliphatic residue, unsubstituted or mono- or polysubstituted; a C ₃ . ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted,

or

denotes S-R ⁹ , O-R ¹⁰ or N(R ¹ R ¹² ),

wherein

R ⁹ and R ⁰ in each case represent C^-aliphatic residue, unsubstituted or mono- or polysubstituted; C ₃ _ ₆ -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C^-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

with the proviso, that if R ⁹ or R ¹⁰ denote a 3 to 7 membered heterocycloaliphatic residue, than the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom,

R ¹ represents C^-aliphatic residue, unsubstituted or mono- or polysubstituted; C ₃ . ₆ - cycloaliphatic residue or a 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1- - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

with the proviso that if R ¹ denotes a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom; and

R ¹² denotes C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted;

or

R ¹ and R ¹² form together with the nitrogen atom connecting them a 3 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted;

R represents C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; or

C ₃ .io-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a Ci. ₄ -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; or

aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ³ denotes a 3 to 10 membered heterocycloaliphatic residue or a heteroaryl, the 3 to 10 membered heterocycloaliphatic residue or the heteroaryl is linked via a carbon atom;

and R ⁴ denotes H or C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; or

R ³ and R ⁴ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; in which an "aliphatic group" and "aliphatic residue" may in each case be branched or unbranched, saturated or unsaturated, in which a "cycloaliphatic residue" and a "heterocycloaliphatic residue" may in each case be saturated or unsaturated, in which "mono- or polysubstituted" with respect to "aliphatic group", "aliphatic residue", "cycloaliphatic residue" and "heterocycloaliphatic residue" relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , Nh^C^-aliphatic residue), N(C-|. ₄ - aliphatic residue) ₂ , NH-C(=0)-C ₁ . aliphatic residue, N(C,. aliphatic residue)-C(=0)-C ₁ . ₄ aliphatic residue, NH-S^O^-C^ aliphatic residue, N(C _-4 aliphatic residue)-S(=0) ₂ -C ₁ _ aliphatic residue, =0, OH, OCF ₃ , O- C _1-4 -aliphatic residue, 0-C(=0)-C . -aliphatic residue, SH, SCF ₃ , S-C^-aliphatic residue, S(=0) ₂ OH,

N(Ci. ₄ -aliphatic residue) ₂ , CN, CF ₃ , CHO, COOH, C-i_ ₄ -aliphatic residue, C(=0)-C ₁ . ₄ -aliphatic residue, C(=0)-0-C ₁ . ₄ -aliphatic residue, C ₃ . ₆ -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, C(=0)NH ₂ , a C(=0)-NH(d. ₄ -aliphatic residue) and C(=0)-N(C ₁ . -aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to "aryl" and "heteroaryl" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , ,

¾ , ^°> , ^ ^' ^, NH(Ci_ ₄ -aliphatic residue), i KC^-aliphatic residue) ₂ , NH-C(=0)-C _1-4 -aliphatic residue, N(C _1-4 aliphatic residue)-C(=0)-C _-4 aliphatic residue, NH-S(=0) ₂ -C ₁ . ₄ aliphatic residue, N(C _1-4 aliphatic residue)-S(=0) ₂ -C ₁ . aliphatic residue, OH, OCF ₃ , 0-C _-4 -aliphatic residue, 0-C(=0)-C ₁ . -aliphatic residue, SH, SCF ₃ , S-C^-aliphatic residue, S(=0) ₂ OH, S(=0) ₂ -C _1-4 -aliphatic residue, SCOk-O-C^-aliphatic residue, S(=0) ₂ -NH(d. ₄ -aliphatic residue), S(=0) ₂ -N(C ₁ . ₄ -aliphatic residue) ₂ , CN, CF ₃ , C(=0)H,

C(=0)OH, d. ₄ -aliphatic residue, C(=0)-C ₁ . ₄ -aliphatic residue, C(=0)-0-C ₁ . -aliphatic residue, C^- cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(=0)NH ₂ , C(=0)-NH(C ₁ .4-aliphatic residue) and C(=0)-N(C ₁ . ₄ -aliphatic residue) ₂ ; in the form of an individual single stereoisomer or a mixture of the stereoisomers in any mixing ratio, and/or in the form of a free compound, a solvate and and/or a physiologically acceptable salt.

Within the scope of this invention, the terms "aliphatic residue" or "aliphatic group" include acyclic saturated or unsaturated aliphatic hydrocarbon radicals, which can be branched or unbranched as well as unsubstituted or mono- or poly-substituted, having from 1 to 10 or from 1 to 8 or from 1 to 6 or from 1 to 4 or from 1 to 2 or from 2 to 6 carbon atoms, that is to say C^o-alkanyls, C ₂ -io-alkenyls and C ₂ -io-alkynyls or C _1-8 -alkanyls, C ₂ . ₈ -alkenyls and C ₂ -8-alkynyls or C^-alkanyls, C ₂ . ₆ -alkenyls and C ₂ -6-alkynyls or C _1-4 - alkanyls, C ₂ -alkenyls and C ₂ -alkynyls or C ₂ . ₆ -alkanyls, C ₂ . ₆ -alkenyls and C ₂ -6-alkynyls. Alkenyls contain at least one C-C double bond and alkynyls contain at least one C-C triple bond. Alkyl is preferably selected from the group comprising methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n- nonyl, n-decyl, ethenyl (vinyl), ethynyl, propenyl (-CH ₂ CH=CH ₂ , -CH=CHCH ₃ , -C(=CH ₂ )CH ₃ ), propynyl (- CH ₂ C≡CH, -C≡CCH ₃ ), butenyl, butynyl, pentenyl, pentynyl, hexenyl and hexynyl, heptenyl, heptynyl, octenyl, octynyl, nonenyl, nonynyl, decenyl and decynyl.

For the purposes of this invention, the terms "cycloaliphatic residue" or "C ₃ .i ₀ -cycloaliphatic residue", "C ₃ . 8-cycloaliphatic residue" and "C ₃ . ₆ -cycloaliphatic residue" denote cyclic aliphatic hydrocarbons having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms or having 3, 4, 5, 6, 7 or 8 carbon atoms or having 3, 4, 5 or 6 carbon atoms, wherein the hydrocarbons can be saturated or unsaturated (but not aromatic), unsubstituted or mono- or poly-substituted. The bonding of the cycloaliphatic residue to the general structure of higher order can take place via any desired and possible ring member of the cycloalkyl radical. The cycloaliphatic residue can also be fused with further saturated, (partially) unsaturated, (hetero) cycloaliphatic, aromatic or heteroaromatic ring systems, that is to say with cycloaliphatic residue, heterocycloaliphatic residue, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. The cycloaliphatic residue radicals can further be bridged one or more times, as, for example, in the case of adamantyl, bicyclo[2.2.1]heptyl or bicyclo[2.2.2]octyl. Cycloalkyl is preferably selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl cyclononyl, cyclodecyl, adamantyl as well as

The term "3 to 10 membered heterocycloaliphatic residue" or "3 to 7 membered heterocycloaliphatic residue" or "heterocycloaliphatic residue" includes aliphatic saturated or unsaturated (but not aromatic) heterocycloaliphatic residues having preferenially from three to ten, that is to say 3, 4, 5, 6, 7, 8, 9 or 10, ring members or from from three to seven, that is to say 3, 4, 5, 6 or 7, ring members in which at least one carbon atom, optionally also two or three carbon atoms, has been replaced by a heteroatom or heteroatom group in each case selected independently of one another from the group consisting of O, S, S(=0), S(=0) ₂ , N, NH and N{C _1-8 -alkyl), preferably N(CH ₃ ), wherein the ring members can be

unsubstituted or mono- or poly-substituted. The bonding of the heterocycloaliphatic residue to the general structure of higher order can take place via any desired and possible ring member of the

heterocycloaliphatic residue. The heterocycloaliphatic residues can also be fused with further saturated, (partially) unsaturated (hetero)cycloaliphatic or aromatic or heteroaromatic ring systems, that is to say with cycloaliphatic residue, heterocycloaliphatic residue, aryl or heteroaryl, which can themselves be un- substituted or mono- or poly-substituted. The term "fused" also optionally includes spirocycles, i.e. an at least bicyclic ring system, wherein the heterocycloaliphatic residue is connected through just one (spiro)atom with a further saturated or (partially) unsaturated (hetero)cycloaliphatic ring system. Example n

Preferred heterocycloaliphatic residues are selected from the group consisting of azetidinyl, aziridinyl, azepanyl, azocanyl, diazepanyl, dithiolanyl, dihydroquinolinyl, dihydropyrrolyl, dioxanyl, dioxolanyl, dioxepanyl, dihydroindenyl, dihydropyridinyl, dihydrofuranyl, dihydroisoquinolinyl, dihydroindolinyl, dihydroisoindolyl, imidazolidinyl, isoxazolidinyl, morpholinyl, oxiranyl, oxetanyl, oxazepanyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, piperidinyl, pyrazolidinyl, pyranyl, tetrahydropyrrolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroindolinyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrahydropyridoindolyl, tetrahydronaphthyl, tetrahydrocarbolinyl, tetrahydro- isoxazolo-pyridinyl, thiazolidinyl, tetrahydroimidazo[1 ,2-a]pyrazinyl, octahydropyrrolo[1 ,2-a]pyrazinyl and thiomorpholinyl. More preferred heterocycloaliphatic residues are pyrrolidinyl, piperidinyl, oxazepanyl, azetidinyl, morpholinyl, piperazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, and dihydroisoindolyl. Most preferred heterocycloaliphatic residues are pyrrolidinyl, piperidinyl, oxazepanyl, azetidinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, and dihydroisoindolyl.

Within the scope of this invention, the term "aryl" denotes aromatic hydrocarbons having up to 14 ring members, inter alia phenyls and naphthyls. Each aryl radical can be unsubstituted or mono- or poly- substituted, it being possible for the aryl substituents to be identical or different and to be in any desired and possible position of the aryl. The aryl can be bonded to the general structure of higher order via any desired and possible ring member of the aryl radical. The aryl radicals can also be fused with further saturated, (partially) unsaturated, (hetero)cycloaliphatic, aromatic or heteroaromatic ring systems, that is to say with cycloaliphatic residue, heterocycloaliphatic residue, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. Examples of fused aryl radicals are benzodioxolanyl and benzodioxanyl. Aryl is preferably selected from the group containing phenyl, 1-naphthyl and 2-naphthyl, each of which can be unsubstituted or mono- or poly-substituted. A particularly preferred aryl is phenyl, unsubstituted or mono- or poly-substituted.

The term "heteroaryl" for the purpose of this invention represents a 5 or 6-membered cyclic aromatic residue containing at least 1 , if appropriate also 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms are each selected independently of one another from the group S, N and O and the heteroaryl residue can be unsubstituted or mono- or polysubstituted; in the case of substitution on the heteroaryl, the substituents can be the same or different and be in any desired and possible position of the heteroaryl. The binding to the superordinate general structure can be carried out via any desired and possible ring member of the heteroaryl residue. The heteroaryl can also be part of a bi- or polycyclic system having up to 14 ring members, wherein the ring system can be formed with further saturated, (partially) unsaturated, (hetero)cycloaliphatic or aromatic or heteroaromatic rings, i.e. with a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl residue, which can in turn be unsubstituted or mono- or polysubstituted. Preferably, the heteroaryl residue is selected from the group consisting of benzofuranyl, benzoimidazolyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzotriazolyl, benzooxazolyl, benzooxadiazolyl, quinazolinyl, quinoxalinyl, carbazolyl, quinolinyl, dibenzofuranyl, dibenzothienyl, furyl (furanyl), imidazolyl, imidazothiazolyl, indazolyl, indolizinyl, indolyl, isoquinolinyl, isoxazoyl, isothiazolyl, indolyl, naphthyridinyl, oxazolyl, oxadiazolyl, phenazinyl, phenothiazinyl, phthalazinyl, pyrazolyl, pyridyl (2-pyridyl, 3-pyridyl, 4- pyridyl), pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, purinyl, phenazinyl, thienyl (thiophenyl), triazolyl, tetrazolyl, thiazolyl, thiadiazolyl and triazinyl. Furyl, pyridyl, oxazolyl, thiazolyl and thienyl are particularly preferred.

Within the scope of the invention, the expressions "linked via C^-aliphatic group" in relation to aryl, heteroaryl, heterocycloaliphatic residue or cycloaliphatic residue is understood that C^-aliphatic group and aryl or heteroaryl or heterocycloaliphatic residue or cycloaliphatic residue have the meanings defined above and the aryl or heteroaryl or heterocycloaliphatic residue or cycloaliphatic residue is bonded to the general structure of higher order via a Ci. -aliphatic group. The aliphatic group can in all cases be saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted. The Ci. - aliphatic group is preferably selected from C _1-4 -alkyl groups, preferably from the group comprising of - CH2-, -CH2CH2 -CH(CH3)-, -CH2CH2CH2-, -CH(CH3)CH2-, -CH(CH2CH3)-, -CH2(CH2)2CH2-,

-CH(CH ₃ )CH ₂ CH ₂ -, -CH ₂ CH(CH ₃ )CH ₂ -, -CH(CH ₃ CH(CH ₃ )-, -CH(CH ₂ CH ₃ )CH2-,-C(CH ₃ ) ₂ CH2-,

-CH(CH ₂ CH ₂ CH ₃ )-, -C(CH ₃ )(CH ₂ CH ₃ )-, -CH=CH-, -CH=CHCH ₂ -, -C(CH ₃ )=CH ₂ -, -CH=CHCH ₂ CH ₂ -, -CH ₂ CH=CHCH ₂ -, -CH=CHCH=CH-, -C(CH ₃ )=CHCH ₂ -, -CH=C(CH ₃ )CH ₂ -, -C(CH ₃ )=C(CH ₃ )-,

-C(CH ₂ CH ₃ )=CH-, -C≡C-, -C≡CCH ₂ - -C≡CCH ₂ CH ₂ -, -C≡CCH(CH ₃ )-, -CH ₂ C≡CCH ₂ - and -C≡CC(CH ₃ ) ₂ -.

In relation with "aliphatic residue", "aliphatic group", "heterocycloaliphatic residue" and "cycloaliphatic residue", the expression "mono- or poly-substituted" is understood as meaning within the scope of this invention the substitution of one or more hydrogen atoms one or more times, for example two, three or four times, in each case independently of one another, by substituents selected from the group comprising F, CI, Br, I, N0 ₂ , NH ₂ ,

aliphatic residue, N^C^-aliphatic residue)-C(=0)-C _1-4 aliphatic residue, NH-S(=0) ₂ -C ₁ _ ₄ -aliphatic residue, N(C _M -aliphatic residue)-S(=0) ₂ -C ₁ . -aliphatic residue, =0, OH, OCF ₃ , 0-C-,_ ₄ -aliphatic residue, 0-C(=0)- Ci- ₄ -aliphatic residue, SH, SCF ₃ , residue, residue), residue) ₂ , CN, CF ₃ , CHO, COOH, C _1-4 -aliphatic residue, C(=0)-C ₁ . ₄ -aliphatic residue, C(=0)-0-C ₁ . ₄ -aliphatic residue, C ₃ . 6-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl,

C(=0)NH ₂ , a C(=0)-NH(C ₁ . ₄ -aliphatic residue) and C(=0)-N(C ₁ _ ₄ -aliphatic residue) ₂ ; wherein

polysubstituted radicals are to be understood as being radicals that are substituted several times, for example two, three or four times, either on different atoms or on the same atom, for example three times on the same carbon atom, as in the case of CF ₃ or CH ₂ CF ₃ , or at different places, as in the case of CH(OH)-CH=CH-CHCI ₂ . A substituent can itself optionally be mono- or poly-substituted. Polysubstitution may take place with the same or with different substituents. Preferred substituents of "aliphatic residue", "aliphatic group", "heterocycloaliphatic residue" or

"cycloaliphatic residue" are selected from the group comprising F, CI, Br, NH ₂ , NH(d_ ₄ -aliphatic residue), N(d-4-aliphatic residue) ₂ , NH-C(=0)-C _ ₄ aliphatic residue, NH-S(=0) ₂ -C . ₄ -aliphatic residue, =0, OH, OCF ₃ , 0-d„ ₄ -aliphatic residue, 0-C(=0)-C ₁ . ₄ -aliphatic residue, S(=0) ₂ -C ₁ . ₄ -aliphatic residue, S(=0) ₂ - NH(d_ -aliphatic residue), S(=0) ₂ -N(d_ ₄ -aliphatic residue) ₂ , CN, CF ₃ , COOH, C^-aliphatic residue, C(=0)-C ₁ . ₄ -aliphatic residue, C3. ₆ -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, C(=0)NH ₂ , C(=0)-NH(d. ₄ -aliphatic residue) and C(=0)-N(d. ₄ -aliphatic residue) ₂ .

In relation with "aryl" and "heteroaryl", the term "mono- or poly-substituted" is understood within the scope of this invention as meaning the substitution of one or more hydrogen atoms of the ring system one or more times, for example two, three or four times, in each case independently of one another, by substituents selected from the group comprising

¾, _0> ¾<\ _¾ ο *°

F, CI, Br, I, N0 ₂ , NH ₂ , , 0 , -/ , f^, NH(d_ ₄ -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , NH- C(=0)-d„ ₄ -aliphatic residue, N(C _1-4 -aliphatic

aliphatic residue, N(C _-4 aliphatic residue)-S(=0) ₂ -d. ₄ -aliphatic residue, OH, OCF ₃ , 0-d. ₄ -aliphatic residue, 0-C(=0)-d. ₄ -aliphatic residue, SH, SCF ₃ , S-d. ₄ -aliphatic residue, S(=0) ₂ OH, S(=0) ₂ -d„ ₄ - aliphatic residue, S(=0) ₂ -0-d. ₄ -aliphatic residue, S(=0) ₂ -NH(C ₁ . ₄ -aliphatic residue), S(=0) ₂ -N(C ₁ . - aliphatic residue) ₂ , CN, CF ₃ , C(=0)H, C(=0)OH, C _1-4 -aliphatic residue, C(=0)-C ₁ . -aliphatic residue, C(=0)-0-C ₁ . ₄ -aliphatic residue, C ₃ . ₆ -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(=0)NH ₂ , residue) ₂ ; on one atom or optionally on different atoms, wherein a substituent can itself optionally be mono- or poly- substituted. Polysubstitution is carried out with the same or with different substituents.

Preferred "aryl" and "heteroaryl" substituents are F; CI; Br; CF ₃ ; CN; d. ₄ -aliphatic residue; phenyl;

naphthyl; pyridyl; thienyl; furyl; C ₃ . ₆ -cycloaliphatic residue; 3 to 7 membered heterocycloaliphatic residue; C(=0)-C ₁ . ₄ -aliphatic residue; C0 ₂ H; C(=0)-0-d. ₄ -aliphatic residue; CONH ₂ ; C(=0)-NH(C ₁ . ₄ -aliphatic residue); C(=0)-N(d_ ₄ -aliphatic residue) ₂ ; OH; 0-d_ ₄ -aliphatic residue; OCF ₃ ; 0-C(=0)-d„ ₄ -aliphatic residue; NH ₂ ; NH(d. ₄ -aliphatic residue); N(C _1-4 -aliphatic residue) ₂ ; N(H)C(=0)-d. ₄ -aliphatic residue; S-C _1-8 -alkyl; SCF ₃ ; S(=0) ₂ C ₁ . ₄ -aliphatic residue; S(=0) ₂ -N(H)d. ₄ -aliphatic residue.

The compounds according to the invention are defined by substituents, for example by R ^A , R ^B and R ^c (1 st generation substituents), which are themselves optionally substituted (2nd generation substituents). Depending on the definition, these substituents of the substituents can in turn themselves be substituted (3rd generation substituents). If, for example, R ^A = aryl (1 st generation substituent), aryl can itself be substituted, for example by d. ₄ -aliphatic residue (2nd generation substituent). This yields the functional group aryl-C- -aliphatic residue. d_ ₄ -aliphatic residue can then in turn itself be substituted, for example by CI (3rd generation substituent). Overall, this then yields the functional group aryl-Ci. ₄ -aliphatic residue- Cl.

In a preferred embodiment, however, the 3rd generation substituents cannot themselves be substituted, that is to say there are no 4th generation substituents. In another preferred embodiment, the 2 ^nd generation substituents may not be resubstituted, i.e. there are then not even any 3 ^rd generation substituents. In other words, in this embodiment, in the case of general formula (I), for example, the functional groups for R ¹ to R ¹³ can each if appropriate be substituted; however, the respective substituents may then for their part not be resubstituted.

In some cases, the compounds according to the invention are defined by substituents which are or carry an aryl or heteroaryl residue, respectively unsubstituted or mono- or polysubstituted, or which form together with the carbon atom(s) or heteroatom(s) connecting them, as the ring member or as the ring members, a ring, for example an aryl or heteroaryl, in each case unsubstituted or mono- or

polysubstituted. Both these aryl or heteroaryl residues and the (hetero)aromatic ring systems formed in this way can if appropriate be condensed with a cycloaliphatic, preferably a C ₃ . ₆ cycloaliphatic residue, or heterocycloaliphatic residue, preferably a 3 to 7 membered heterocycloaliphatic residue, or with aryl or heteroaryl, e.g. with a C3-6 cycloaliphatic residue such as cyclopentyl, or a 3 to 7 membered

heterocycloaliphatic residue such as morpholinyl, or an aryl such as phenyl, or a heteroaryl such as pyridyl, wherein the cycloaliphatic or heterocycloaliphatic residues, aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.

In some cases, the compounds according to the invention are defined by substituents which are or carry a heterocycloaliphatic residue or heterocycloaliphatic residue, in each case unsubstituted or mono- or poly-substituted, or which, together with the carbon atom(s) or heteroatom(s) joining them as ring member(s), form a ring, for example a cycloaliphatic residue or heterocycloaliphatic residue, in each case unsubstituted or mono- or poly-substituted. Both these cycloaliphatic or heterocycloaliphatic residue and the aliphatic ring systems formed can optionally be fused with aryl or heteroaryl, that is to say with an aryl such as phenyl or with a heteroaryl such as pyridyl, it being possible for the aryl or heteroaryl radicals so fused to be unsubstituted or mono- or poly-substituted.

Within the scope of the present invention, the symbol used in the formulae denotes a link of a corresponding residue to the respective superordinate general structure.

The expression "salt formed with a physiologically acceptable acid" is understood within the scope of this invention as meaning salts of the active ingredient in question with inorganic or organic acids that are physiologically acceptable - in particular when used in humans and/or mammals. The hydrochloride is particularly preferred.

Physiologically acceptable salts with cations or bases are salts of the compound in question - in the form of the anion with at least one, preferably inorganic cation - that are physiologically acceptable - in particular when used in humans and/or mammals.

The present invention further relates to a compound of general formula (I), wherein

A represents CR ⁵ or N;

A ² represents CR ⁶ , N, O, S or NR ⁷ ;

A ³ represents CR or N, and

n denotes 0 or 1 ,

on the condition, that

if n denotes 0, then A ² represents O, S or NR ⁷ , or

if n denotes 1 , then A ² represents CR ⁶ or N,

wherein

R ⁵ is selected from F, CI, Br, CN, CH ₃ , CF ₃ , CHF ₂ , CH ₂ F, OCH ₃ , C ₂ H ₅ , SCH ₃ , OCF ₃ , OCHF ₂ or OCH ₂ F; R ⁶ is selected from H, F, CI, Br, CN, CH ₃ , CF ₃ , CHF ₂ , CH ₂ F, OCH ₃ , C ₂ H ₅ , SCH ₃ , OCF ₃ , OCHF ₂ or OCH ₂ F; R ⁷ represents C^-aliphatic residue or Cs-s-cycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NhKC^-aliphatic residue), NiC^-aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C^-aliphatic residue, CF ₃ , CN, C^-aliphatic residue and C(=0)OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-Ci_ ₄ -aliphatic residue,

R ⁸ is selected from H, F, CI, Br, CN, CH ₃ , CF ₃ , CHF ₂ , CH ₂ F, OCH ₃ , C ₂ H ₅ , SCH ₃ , OCF ₃ , OCHF ₂ or 0CH ₂ F; with the proviso, that,

if n denotes 1 , then at least one of A ¹ , A ² and A ³ denotes N,

with the proviso, that

if n denotes 1 and A ³ denotes N, then A ¹ and/or A ² denotes N,

and with the proviso, that

if n denotes 1 and A ² denotes N and A ¹ denotes CR ⁵ and A ³ denotes CR ⁸ , then R ⁵ denotes F, CI, CH ₃ , CF ₃ , CHF ₂ or CH ₂ F;

R ¹³ represents H or d. ₄ -aliphatic residue,

R ¹ denotes d. ₁₀ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , Nh^C^-aliphatic residue), NtC^-aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, C^-aliphatic residue and C(=0)OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d- ₄ -aliphatic residue,

or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C ₁ . ₄ -aliphatic residue), N(C-|. -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, C _1- - aliphatic residue, C(=0)OH, C^e-cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-C _1- -aliphatic residue, and

wherein the C ₃ _ ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C ₁ . ₄ - aliphatic residue), N(Ci. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-Ci _-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aiiphatic residue and C(=0)-OH, and wherein the C ₃ „i ₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C _-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(d- ₄ -aliphatic residue) ₂ , OH, =0, 0-C,. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue and C(=0)0H, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci. ₄ -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, 0-C-|. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. -aliphatic residue, CF ₃ , CN, C,. ₄ -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)0CH ₃ and

C(=0)OC ₂ H ₅ , C ₃ . ₆ -cycloaliphatic residue, a 3 to 7 membered heterocycloaliphatic residue, ,

^¾0 >

i , , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-Ci. ₄ -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d- ₄ - aliphatic residue) ₂ , OH, 0-d_ ₄ -aliphatic residue, OCF ₃ , OCH ₂ CH ₂ 0H, OCH ₂ OCH ₃ , SH, SCF ₃ , S-d_ ₄ -aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)-OCH ₃ and C(=0)-OC ₂ H ₅ , and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ - aliphatic residue), an N(C _-4 -aliphatic residue) ₂ , OH, =0, 0-C - -aliphatic residue, 0CF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)OH, and wherein the aryl or the heteroaryl residue may in each case be optionally linked via a d-4-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN and C(=0)0H, denotes d. ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)OH,

wherein the d. -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-C _1-4 -aliphatic residue,

or

denotes C ₃ . ₆ -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d_ ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, O-C- -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d_ ₄ -aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue and C(=0)OH,

wherein the d_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, and

wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a d. ₄ -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. -aliphatic residue), N(d. -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, 0CF ₃ , SH, SCF ₃ , S-C^-aliphatic residue, CF ₃ , CN, d.4-aliphatic residue and C(=0)OH,

or

denotes S-R ⁹ , O-R ¹⁰ or N(R ¹¹ R ¹² ),

wherein

R ⁹ and R ¹⁰ in each case represent d_ ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, d.4-aliphatic residue and C(=0)OH,

wherein the C^^aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, or in each case represent C ₃ . ₆ -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S- d. ₄ -aliphatic residue, CF ₃ , CN, d_ ₄ -aliphatic residue, C(=0)OH, C ₃ - ₆ -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue,

wherein the d. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O-d-4-aliphatic residue, and wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), an NCC^-aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C^-aliphatic residue, CF ₃ , CN, d.4-aliphatic residue and C(=0)OH, and

wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 7 membered

heterocycloaliphatic residue may in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. -aliphatic residue), N(Ci. -aliphatic residue) ₂ , OH, =0, 0-C _1-4 -aliphatic residue, 0CF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, C _1- -aliphatic residue and C(=0)OH,

on the condition that if R ⁹ or R ⁰ denote a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom,

R ¹ denotes d. ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci. ₄ -aliphatic residue), N^C^-aliphatic residue) ₂ , OH, =0, 0-d_ ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d- ₄ -aliphatic residue, CF ₃ , CN, d_ ₄ -aliphatic residue, C(=0)-0-d. ₄ -aliphatic residue, and C(=0)OH,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, or denotes C ₃ . ₆ -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(C ₁ . ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, 0CF ₃ , SH, SCF ₃ , S-d. ₄ - aliphatic residue, CF ₃ , CN, C _-4 -aliphatic residue, C(=0)OH, C(=0)-0-C ₁ . ₄ -aliphatic residue, C ₃ . ₆ -cycloaliphatic residue, and a 3 to 7 membered heterocycloaliphatic residue, wherein the d. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-Ci. ₄ -aliphatic residue, and wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, d. -aliphatic residue and C(=0)-OH, and

wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 7 membered

heterocycloaliphatic residue may in each case optionally linked via a Ci„ ₄ -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C ₁ . ₄ -aliphatic residue), N(C _1- -aliphatic residue) ₂ , OH, =0, O-d-4-aliphatic residue, C(=0)-0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)OH,

on the condition that if R ¹ denotes a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom,

and

R ¹² denotes C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d_ ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)OH,

wherein the d. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, or

R ¹ and R ¹² form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. -aliphatic residue), N(Ci- ₄ -aliphatic residue) ₂ , OH, =0, 0-Ci. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C _1-4 -aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)-OH, Cs-6-cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue,

wherein the C _1-4 -a!iphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-C . ₄ -aliphatic residue, and wherein the C ₃ _ ₆ -cycloaliphatic residue and the 3 to 7 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, Ci-4-aliphatic residue and C(=0)OH, and

wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ¹¹ and R ¹² together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, 0-d_ ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d_ ₄ -aliphatic residue, CF ₃ , CN, d. ₄ - aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-OCH ₃ and C(=0)- c residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or poiysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ - aliphatic residue,

and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or poiysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d- ₄ -aliphatic residue), N(Ci _-4 -aliphatic residue) ₂ , OH, O- C _1-4 -aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S-d. 4-aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , and wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or poiysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d. -aliphatic residue) ₂ , OH, =0, 0-d. -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-Ci. ₄ -aliphatic residue, CF ₃ , CN, d. -aliphatic residue and C(=0)OH, denotes d_i ₀ -aliphatic residue, unsubstituted or mono- or poiysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue) N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue, residue and C(=0)OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or poiysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue,

or denotes C^o-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or poiysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d_ ₄ -aliphatic residue), N(C _lJf -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, d. - aliphatic residue, C(=0)OH, residue, Cs-e-cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue,

wherein the d_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or poiysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or poiysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d- - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, =0, 0-d_ ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, d_ ₄ -aliphatic residue and C(=0)OH, and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a d_ -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, =0, 0-C _1-4 -aliphatic residue, C(=0)-0-C -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d_ ₄ -aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue and C(=0)OH, on the condition that if R ³ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci. ₄ -aliphatic residue), N(d_ ₄ -aliphatic residue) ₂ , OH, 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C^-aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ ,

>

C(=0)OC ₂ H ₅ , C ₃ . ₆ -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue,

*V , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-Ci_ ₄ -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. -aliphatic residue), N(d_ ₄ - aliphatic residue) ₂ , OH, 0-C,. ₄ -aliphatic residue, OCF ₃ , 0CH ₂ CH ₂ 0H, OCH ₂ OCH ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci_ ₄ - aliphatic residue), an N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, d_ ₄ -aliphatic residue and C(=0)OH, and wherein the aryl or the heteroaryl residue may in each case be optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d_ ₄ -aliphatic residue, CF ₃ , CN and C(=0)OH, denotes H or C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C _1-4 -aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue and C(=0)OH, wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-Ci. -aliphatic residue,

or

R ³ and R ⁴ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NF^C^-aliphatic residue), N(d.4-aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C^-aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)OH, C ₃ - ₆ -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, OCF ₃ , CF ₃ and unsubstituted O-C^-aliphatic residue, and wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C - - aliphatic residue), N^C^-aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, C^-aliphatic residue and C(=0)OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci. ₄ -aliphatic residue), N(Ci. ₄ -aliphatic residue) ₂ , OH, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C-|. ₄ -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , liphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with a C ₃ . 1 ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, wherein the C^o-cycloaliphatic residue or the 3 to 10 membered

heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C _1- - aliphatic residue), N(C _J( -aliphatic residue) ₂ , =0, OH, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C -aliphatic residue, CF ₃ , CN, C^-aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , C(=0)OC ₂ H ₅ , C ₃ . ₆ -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O-d-4- aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d_ ₄ -aliphatic residue), N(C ₁ . ₄ -aliphatic residue) ₂ , OH, O- d-4-aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S-d. 4-aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)0C ₂ H ₅ , and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, C - -aliphatic residue and C(=0)OH.

Within the scope of the present invention, the central structural element of general formula (I)

represents a 5-membered or a 6-memebered heteroaryl residue. The residue is aromatic as depicted by the dashed bond presentation.

If n represents 1 , then central structural element in general formula (I) represents a 6-membered heteroaryl residue (la):

(I) (la)

If n represents 0, then the partial structure in general formula (I) represents a 5-membered heteroaryl residue (lb) or (lc):

In one embodiment of the present invention, the compound according to general formula (I) is characterized in that

n denotes 0 and the compound is represented by general formula (lb).

In one preferred embodiment of the present invention, the compound according to general formula (I) is characterized in that

n denotes 0 and the compound is represented by general formula (lb),

wherein

presents CR ⁸ (lb-1 )

; or

resents CR ⁸ (lb-2)

or

A ² represents NR ⁷ and A ³ represents CR ⁸ (lb-3)

A ² represents O and A ³ represents N (lb-4)

A ² represents S and A ³ represents N (lb-5)

A ² represents NR ⁷ and A ³ represents N (lb-6)

In one particularly preferred embodiment, the compound according to general formula (I) is characterized in that

n denotes 0 and the compound is represented by general formula,

wherein

A ² represents O and A ³ represents N (lb-4);

or

A ² represents S and A ³ represents N (lb-5);

or

A ² represents NR ⁷ and A ³ represents N (lb-6).

In another embodiment of the present invention, the compound according to general formula (I) is characterized in that

n denotes 1 and the compound is represented by general formula (la), wherein

1 represents N and A ² represents CR ⁶ and A ³ represents CR ⁸ (la-1 )

nts N and A ³ represents CR ⁸ (la

A represents N and A ² represents N and A ³ represents CR ⁸ (la-3)

; or

A ¹ represents N and A ² represents CR ⁶ and A ³ represents N (la-4)

A ¹ represents CR ⁵ and A ² represents N and A ³ represents N (la

A ¹ represents N and A ² represents N and A ³ represents N (la-6)

In a preferred embodiment, the compound according to general formula (I) is characterized in that n denotes 1 and the compound is represented by general formula (la), wherein

A ¹ represents N and A ² represents CR ⁶ and A ³ represents CR ⁸ (la-1 ); or

A ¹ represents CR ⁵ and A ² represents N and A ³ represents CR ⁸ (la-2); or

A ¹ represents N and A ² represents CR ⁶ and A ³ represents N (la-4); or

A ¹ represents CR ⁵ and A ² represents N and A ³ represents N (la-5).

Furthermore, the residues R ⁵ , R ⁶ , R ⁷ and R ⁸ are particularily selected.

In another embodiment of the invention, R ⁵ denotes F, CI, CH ₃ , OCH ₃ or CH ₂ CH ₃ .

In yet another embodiment of the invention, R ⁶ denotes H.

In yet another embodiment of the invention, R ⁷ denotes CH ₃ , CH ₂ CH ₃ or cyclopropyl.

In yet another embodiment of the invention, R ⁸ denotes H.

In a preferred embodiment, the compound according to general formuls (I) is characterized in that R ⁵ denotes F, CI, CH ₃ , OCH ₃ or CH ₂ CH ₃ ; and/or

R ⁶ denotes H; and/or

R ⁷ denotes CH ₃ , CH ₂ CH ₃ or cyclopropyl; and/or

R ⁸ denotes H.

In one embodiment of the compound according to general formula (I),

R ¹³ represents H or C,. ₄ -aliphatic residue.

In a preferred embodiment of the compound according to general formula (I), R ¹³ represents H or CH ₃ . In a preferred embodiment of the compound according to general formula (I),

R ¹ denotes C _{- 0} -aliphatic residue, preferably d_ ₈ -aliphatic residue, unsubstituted or mono- or

polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d_ ₄ -aliphatic residue), N(Ci. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF3, SH, SCF ₃ , S-d. ₄ -aliphatic residue, residue, CF ₃ , CN, d. ₄ -aliphatic residue and C(=0)-OH,

preferably denotes d_ ₁₀ -aliphatic residue, more preferably a d. ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d_ ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d_ ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d-4-aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)-OH, wherein the Ci. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, or denotes C ₃ . ₁₀ -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C _1-4 -aliphatic residue, CF ₃ , CN, Ci„ ₄ - aliphatic residue, C(=0)-OH, C^ cycloaliphatic residue, and 3 to 7 membered

heterocycloaliphatic residue,

wherein the d-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and unsubstituted 0-d. -aliphatic residue, and

wherein the C ₃ _ ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ - aliphatic residue), an N(d_ ₄ -aliphatic residue) ₂ , OH, =0, an O-d-4-aliphatic residue, OCF3, SH, SCF ₃ , S-C _1-4 -aliphatic residue, CF ₃ , CN, d_ ₄ -aliphatic residue and C(=0)OH, and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-4 aliphatic group, preferably a d_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci. ₄ -aliphatic residue), N(d_ - aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)OH, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S _: d. -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , )OC ₂ H ₅ , C ₃ . ₆ -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, ₍ t> £> benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the Ci _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O-C- -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NHtC- -aliphatic residue), N(C _1-4 - aliphatic residue) ₂ , OH, O-C^ aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S-d.4-aliphatic residue, CF ₃ , CN, C^-aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci. ₄ - aliphatic residue), NiC^-aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C^-aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)OH, and wherein the aryl or the heteroaryl residue may in each case be optionally linked via a Ci_ ₄ - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci _-4 -aliphatic residue), N(d.4-aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C^-aliphatic residue, CF ₃ , CN and C(=0)OH.

In a further embodiment of the invention, the compound according to general formula (I), the residue 1 represents the partial structure (T1)

wherein

m denotes 0, 1 , 2, 3 or 4, preferably denotes 0, 1 , 2 or 3, more preferably denotes 0, 1 , or 2, R ^1a and R ^1b each independently of one another represent H, F, CI, Br, I, N0 ₂ , NH ₂ , NH(C-i_ ₄ aliphatic residue), ^C^-aliphatic residue) ₂ , OH, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C^ aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue or C(=0)-OH, or together denote =0,

preferably each independently of one another represent H, F, CI, Br, I, NH ₂ , NH(C _1-4 -aliphatic residue), NCC^-aliphatic residue) ₂ , OH, O-C^-aliphatic residue or C ₁ _ ₄ -aliphatic residue, or together denote =0,

more preferably each independently of one another represent H, F, CI, Br, I, OH, 0-Ci. ₄ -aliphatic residue or C^-aliphatic residue, or together denote =0, even more preferably each independently of one another represent H, F, OH, O- C _1-4 -aliphatic residue or C^-aliphatic residue, or together denote =0, and denotes d. ₄ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, S(=0) ₂ -C ₁ . ₄ -aliphatic residue, CF ₃ , CN, C - -aliphatic residue and C(=0)-OH, preferably denotes C _1- -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d_ ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ - aliphatic residue, CF ₃ , CN, d-4-aliphatic residue and C(=0)OH, or denotes C ₃ . ₁₀ -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), NKC^-aliphatic residue) ₂ , OH, =0, 0-d.4-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, d. ₄ - aliphatic residue, C(=0)OH, C^-cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, preferably when m is≠ 0,

wherein the d_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, and

wherein the C ₃ - ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d.4- aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d_ ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d_ ₄ -aliphatic residue, CF ₃ , CN, Ci. ₄ -aliphatic residue and C(=0)-OH, or denotes

-preferably when m is 0 or 2, more preferably when m is 0- aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d_ ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, 0-d- ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C _1- -aliphatic residue,

C(=0)OC ₂ H ₅ , C ₃ .

, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

preferably when m is = 0,

wherein the d_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d_ ₄ - aliphatic residue) ₂ , OH, 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d_ ₄ -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , C(=0)OC ₂ H ₅ , and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci. - aliphatic residue), N(d_ ₄ -aliphatic residue) ₂ , OH, =0, 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue and C(=0)OH.

Preferably,

R ¹ represents the partial structure (T1 ),

wherein

m denotes 0, 1 , or 2,

R ^1a and R ^1b each independently of one another represent H, F, CI, Br, I, 0-C,. -aliphatic residue or d- 4-aliphatic residue,

and

R ^1c denotes d. ₄ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, 0-Ci. -aliphatic residue, CF ₃ and Ci_ 4-aliphatic residue,

wherein the d. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and 0-Ci. ₄ -aliphatic residue,

or

denotes C ₃ . ₁₀ -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, 0-d. ₄ -aliphatic residue, CF ₃ and d. -aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and unsubstituted 0-C _1- -aliphatic residue, or

denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0-C,. ₄ -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , C(=0)OC ₂ H ₅ , C ₃ . ₆ - cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,

wherein benzyl, phenyl, thienyl and pyridyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0-d. ₄ -aliphatic residue, OCF ₃ , CF ₃ , CN, d_ ₄ -aliphatic residue, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, O-C^-aliphatic residue, OCF ₃ , CF ₃ C _1-4 -aliphatic residue and C(=0)OH.

In a further preferred embodiment of the compound according to general formula (I), the residue

R ¹ represents the partial structure (T1),

wherein

m is 0, 1 or 2, preferably 0 or 2, more preferably 2, and

R ^1a and R ^1b each independently of one another represent H, F, OH, O-C^-aliphatic residue or C^- aliphatic residue, preferably H, F, OH, CH ₃ or OCH ₃ ;

R ^c denotes C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, CN, OH, unsubstituted 0-Ci„ ₄ - aliphatic residue, CF ₃ and unsubstituted C^-aliphatic residue, preferably denotes C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, unsubstituted O-C^-aliphatic residue, CF ₃ , and unsubstituted C-,. 4-aliphatic residue, or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, unsubstituted O-C^-aliphatic residue, CF ₃ , and unsubstituted C _-4 -aliphatic residue,

or

wherein

m is 0 or 2, more preferably 0, and

R ^1a and R ¹ each independently of one another represent H, F, OH, 0-C _-4 -aliphatic residue or C _1-4 - aliphatic residue, preferably H, F, OH, CH ₃ or OCH ₃ ; and

R ^1c denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, residue,

OCF ₃ , OCF ₂ H, SCF ₃ , N0 ₂ , N C^-aliphatic residue) ₂ , , ^ , CF ₃ , CN, C^-aliphatic residue, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , C(=0)OC ₂ H ₅ and phenyl,

preferably denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , CN, ^-aliphatic residue, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , C(=0)OC ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , OCH ₃ , CF ₃ and OCF ₃ . Preferably,

R ¹ represents the partial structure (T1),

wherein

m denotes 1 or 2,

R ^1a and R ^1b represent H,

R ^1c denotes d-4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, O-C^-aliphatic residue, CF ₃ and d.

4-aliphatic residue,

or

denotes C^o-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, 0-d. ₄ -aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, or

m denotes 0 and

R ^1c denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0-d. ₄ -aliphatic residue, OCF ₃ , CF ₃ , CN, d-4-aliphatic residue, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , C(=0)OC ₂ H ₅ , C ₃ . ₆ - cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,

wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0-d. ₄ -aliphatic residue, OCF ₃ , CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, 0-Ci. ₄ -aliphatic residue, OCF ₃ , CF ₃ d. ₄ -aliphatic residue and C(=0)0H.

In another embodiment of the present invention, the compound according to general formula (I) is characterized in that

R ² denotes d. _e -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d_ -aliphatic residue), N(d.4-aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, 0CF ₃ , SH, SCF ₃ , S-d^-aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue and C(=0)OH,

wherein the d. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0CF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, or

denotes C ₃ - ₆ -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d_ ₄ -aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C _1-4 -aliphatic residue, CF ₃ , CN, C^-aliphatic residue and C(=0)OH,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 7 membered

heterocycloaliphatic residue may in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NI- C^-aliphatic residue), r^C^-aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C^-aliphatic residue, CF ₃ , CN, C^-aliphatic residue and C(=0)OH,

or

denotes S-R ⁹ , O-R ¹⁰ or N(R ¹¹ R ¹² ),

wherein

R ⁹ and R ⁰ in each case represent C^e-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci_ -aliphatic residue), N(C,. ₄ -aliphatic residue) ₂ , OH, =0, Ο-Ο^- aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C _1-4 -aliphatic residue, CF ₃ , CN, C _-4 -aliphatic residue and C(=0)OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, or in each case represent C ₃ . ₆ -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), NCC^-aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S- Ci _-4 -aliphatic residue, CF ₃ , CN, C^-aliphatic residue, C(=0)OH, C ₃ . ₆ -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue,

wherein the Ci- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-C ₁ . ₄ -aliphatic residue, and wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NHiC^-aliphatic residue), an N(C _-4 -aliphatic residue) ₂ , OH, =0, O-d^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C^-aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)OH, and

wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 7 membered

heterocycloaliphatic residue may in each case optionally linked via a C^-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-Ci.4-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d_ ₄ -aliphatic residue, CF _3l CN, d- ₄ -aliphatic residue and C(=0)OH,

on the condition that if R ⁹ or R ¹⁰ denote a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom,

R ¹¹ denotes d. ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. - aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C _1-4 -aliphatic residue, CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)-0-C _1-4 -aliphatic residue, and C(=0)OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d_ -aliphatic residue, or denotes C ₃ . ₆ -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci_ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-d- ₄ -aliphatic residue, 0CF ₃ , SH, SCF ₃ , S-d. ₄ - aliphatic residue, CF ₃ , CN, C _-4 -aliphatic residue, C(=0)OH, C(=0)-0-C ₁ . ₄ -aliphatic residue, C ₃ . ₆ -cycloaliphatic residue, and a 3 to 7 membered heterocycloaliphatic residue, wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, and wherein the C ₃ _ ₆ -cycloaliphatic residue and the 3 to 7 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ -aliphatic residue), N(d_ ₄ -aliphatic residue) ₂ , OH, =0, 0-Ci. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d_ -aliphatic residue, CF ₃ , CN, Ci. ₄ -aliphatic residue and C(=0)-OH, and

wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 7 membered

heterocycloaliphatic residue may in each case optionally linked via a d. ₄ -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(Ci. ₄ -aliphatic residue), N(d. -aliphatic residue) ₂ , OH, =0, 0-Ci. ₄ -aliphatic residue, C(=0)-0-d_ ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)OH,

on the condition that if R ¹¹ denotes a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom,

and

R ¹² denotes d. ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(d. ₄ - aliphatic residue), NiC^-aliphatic residue) ₂ , OH, =0, 0-C _1- -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d. ₄ -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-C _1-4 -aliphatic residue, or

R ¹¹ and R ¹² form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NH(C _1- - aliphatic residue), NCC^-aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d.4-aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(=0)-OH, C^- cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C ₃ _ ₆ -cycloaliphatic residue and the 3 to 7 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NHCC^-aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C _1-4 -aliphatic residue, CF ₃ , CN, C _-4 -aliphatic residue and C(=0)OH, and

wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ¹ and R ¹² together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NHiC^-aliphatic residue), NiC^-aliphatic residue) ₂ , OH , 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C^-aliphatic residue, CF ₃ , CN, Ci _-4 - aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-OCH ₃ and C(=0)- OC ₂ H ₅ , C ₃ _ ₆ -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue,

oxazolyl,

wherein the Ci _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-C-|. ₄ - aliphatic residue,

and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , NHiC^-aliphatic residue), NiC^-aliphatic residue) ₂ , OH, O- C-i-4-aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S-C^

4-aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , N^C^-aliphatic residue), NiC^-aliphatic residue) ₂ , OH, =0, 0-Ci. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C^-aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)OH.

Preferably,

R ² denotes a Ci. ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C-|. ₄ -aliphatic residue, CF ₃ , CN and C^-aliphatic residue,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O-C^-aliphatic residue, or denotes C ₃ . ₆ -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, O-C ₁ .4 aliphatic residue, OCF ₃ , SH, SCF ₃ , S-C _1-4 aliphatic residue, CF ₃ , CN and C _1-4 -aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted 0-Ci_ ₄ -aliphatic residue, and

and wherein the C ₃ _ ₆ -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a C^-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, O-C^-aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ CN, and C,. 4-aliphatic residue.

or

R ² denotes S-R ⁹ or O-R ¹⁰ ,

wherein

R ⁹ and R ¹⁰ in each case represent C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , S-d.4-aliphat.ic residue, N^C^-aliphatic residue), NiC^-aliphatic residue) ₂ , CF ₃ , and C- -aliphatic residue,

wherein the Ci_ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and unsubstituted 0-Ci. ₄ -aliphatic residue, or in each case denote C^-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-d. -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C^-aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and unsubstituted O-Ci.4-aliphar.ic residue,

and wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a Ci. ₄ -aliphatic group, preferably a C^-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-C _-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, and Ci- ₄ -aliphatic residue,

on the condition that if R ⁹ or R ¹⁰ denotes a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom,

or

R ² denotes N(R ¹¹ R ¹² ),

wherein

R ¹¹ denotes C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, 0-C ₁ _ ₄ -aliphatic residue, 0CF ₃ , SCF ₃ , CF ₃ and d. ₄ -aliphatic residue,

wherein the C ₁ _ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue,

or denotes a C ₃ . ₆ -cycloaliphatic residue or a 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-d. -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , and Ci_ ₄ - aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and unsubstituted 0-C _1-4 -aliphatic residue, and

and wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a d. ₄ -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-d. ₄ -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN and C _1-4 -aliphatic residue, on the condition that if R ¹¹ denotes a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom,

and wherein

R ¹² denotes d. ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-Ci_ ₄ -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN, and d. ₄ -aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, CF ₃ and unsubstituted 0-C _1-4 -aliphatic residue, and R ¹² form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 3 to 7 membered heterocycloaliphatic residue, more preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl and piperazinyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, O-C^-aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN, and C _1-4 -alip atic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and unsubstituted 0-Ci. -aliphatic residue,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ¹¹ and R ¹² together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, 0-d. ₄ -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN, C^-aliphatic residue, C(=0)OH, C ₃ . ₆ cycloaliphatic residue, a 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, and pyridyl,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF3, CF ₃ and unsubstituted 0-Ci. ₄ -aliphatic residue, and

wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, 0-C _1-4 -aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SCF ₃ , CF ₃ , CN, Ci.4-aliphatic residue, and C(=0)OH, and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, d. ₄ -aliphatic residue and C(=0)OH.

More preferably,

R ² denotes Ci_ ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, OH, =0, O-C^-aliphatic residue, OCF ₃ , CF ₃ and C^-aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case is unsubstituted, or denotes C ₃ . ₆ -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-C _1- aliphatic residue, OCF ₃ , CF ₃ and C^-aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or unsubstituted O-C^-aliphatic residue,

and wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a unsubstituted Ci. ₄ -aliphatic group,

or

R ² denotes S-R ⁹ or O-R ¹⁰ ,

wherein

R ⁹ and R ⁰ in each case denote d. ₆ -aliphatic residue,

unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-Ci. ₄ -aliphatic residue, OCF ₃ , CF ₃ and C _1-4 -aliphatic residue,

wherein the Ci. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, CF ₃ and unsubstituted 0-Ci„ ₄ -aliphatic residue,

or in each case denote C^-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent , selected from the group consisting of F, CI, OH, =0, O-C^ aliphatic residue, OCF ₃ , CF ₃ , and 4-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and unsubstituted 0-C _1-4 -aliphatic residue, and

wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be linked, preferably is linked, via an unsubstituted C^-aliphatic group, on the condition that if R ⁹ orR ¹⁰ denotes a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom,

or

R ² denotes N(R ¹¹ R ¹² ),

wherein

R ¹¹ denotes C^-aliphatic residue,

unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, O-C^-aliphatic residue, OCF ₃ , CF ₃ , and C^-aliphatic residue

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, CF ₃ and unsubstituted 0-C _1-4 -aliphatic residue,

or

R ¹¹ denotes C ₃ . ₇ -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, O-C^ aliphatic residue, OCF ₃ , CF ₃ , and a C^-aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and unsubstituted O-C^-aliphatic residue, and

wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may be linked via an unsubstituted d. ₄ -aliphatic group,

on the condition that if R ¹¹ denotes a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, and

R ¹² denotes unsubstituted C - -aliphatic residue,

preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl and tert.-butyl, more preferably selected from the group consisting of methyl and ethyl,

or

R ¹¹ and R ¹² form together with the nitrogen atom connecting them a 3 to 7 membered

heterocycloaliphatic residue, preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, and azetidinyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-C _-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, and C^-aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, CF ₃ and unsubstituted 0-Ci. ₄ -aliphatic residue, and wherein the 3 to 7 membered heterocycloaliphatic residue formed by R ¹¹ and R ¹² together with the nitrogen atom connecting them may optionally be fused with phenyl or pyridyl, wherein the phenyl or pyridyl residues fused in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , CN, C^-aliphatic residue, benzyl, phenyl, and pyridyl,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, and unsubstituted O-C^-aliphatic residue, and wherein benzyl, phenyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OCH ₃ , OCF ₃ , CF ₃ , and C _-4 -aliphatic residue.

More preferably,

R ² denotes methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl,

isopentyl, neopentyl, n-hexyl, ethenyl or propenyl,

in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, 0-Ci. ₄ -aliphatic residue, CF ₃ and C _1- -aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and an 0-C-i- ₄ -aliphatic residue, preferably OCH ₃ , more preferably in each case unsubstituted,

wherein the C^-aliphatic residue in each case is unsubstituted, or denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, oxetanyl, piperidinyl, ^■ tetrahydrofuranyl, or tetrahydropyranyl,

preferably denotes cyclopropyl or tetrahydropyranyl,

more preferably cyclopropyl,

in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, O-C^-aliphatic residue, CF ₃ and C^-aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI and 0-Ci. ₄ -aliphatic residue, preferably OCH ₃ , more preferably in each case unsubstituted,

wherein the C^-aliphatic residue in each case is unsubstituted, and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, oxetanyl, piperidinyl, tetrahydrofuranyl, and tetrahydropyranyl may in each case be optionally bridged via an unsubstituted C _1-4 -aliphatic group, preferably via an unsubstituted C _-2 -aliphatic group, denotes S-R ⁹ or O-R ¹⁰ ,

wherein

R ⁹ and R ¹⁰ in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec. -butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl and propenyl, in each case

unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, and O-C^-aliphatic residue,

wherein the C^-aliphatic residue in each case is unsubstituted, or in each case denote cyclopropyl, cyclobutyl, cyclopentyl cyclohexyl, oxetanyl, piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl, preferably cyclopropyl or oxetanyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, O-C^-aliphatic residue, CF ₃ and d. ₄ -aliphatic residue,

preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI and O-C^-aliphatic residue, more preferably in each case unsubstituted,

wherein the C _-4 -aliphatic residue in each case is unsubstituted, and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, oxetanyl, piperidinyl, tetrahydrofuranyl, and tetrahydropyranyl may in each case be optionally linked via an unsubstituted d^-aliphatic group,

on the condition that if R ⁹ or R ⁰ denotes piperidinyl, oxetanyl, tetrahydrofuranyl, or

tetrahydropyranyl, each of these residues is linked via a carbon atom, or

R ² denotes N(R ¹¹ R ¹² ),

wherein

R ¹¹ denotes C^-aliphatic residue,

unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, =0, OH and OCH ₃ ,

preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI and OCH ₃ ,

more preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F and 0CH ₃ ,

preferably denotes unsubstituted C^e-aliphatic residue,

more preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n- butyl, isobutyl, sec-butyl, tert. -butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl, and

R ¹² denotes methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec. -butyl or tert.-butyl,

more preferably methyl or ethyl,

or

R ¹¹ and R ¹² form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl,

in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, O-C^ aliphatic residue and C _1-4 -aliphatic residue,

more preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI and O-C^ aliphatic residue, preferably form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted.

In a particular preferred embodiment of the present invention, the compound according to general formula

(I) is characterized in that

R ² is selected from the group consisting of

CH3 ₁ C2H5, CH2CH2CH3, CH(CH3)2, CH CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH ₂ CH3, C(CH ₃ ) ₃ , CH ₂ -cyclopropyl, OCH ₃ , OC ₂ H ₅ , OCH ₂ CH ₂ CH ₃ , OCH(CH ₃ ) ₂ , O-cyclopropyl, SCH ₃ , SC2H5, SCH ₂ CH ₂ CH ₃ , SCH(CH ₃ ) ₂ , S-cyclopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N(CH ₃ ) ₂ , N(CH ₃ )C ₂ H ₅ , N(CH ₃ )CH ₂ CH ₂ CH3, N(CH ₃ )CH(CH ₃ ) ₂ , N(CH ₃ )-cyclopropyl, N(C ₂ H ₅ ) ₂ , N(C ₂ H ₅ )CH ₂ CH ₂ CH3, N(C ₂ H ₅ )CH(CH ₃ ) ₂ , N(C ₂ H ₅ )- cyclopropyl, N-aziridinyl, N-azetidinyl, N-pyrrolidinyl, N-piperidinyl or N-morpholinyl, in each case unsubstituted or mono- or polysubstituted with F, OH and/or OCH ₃ .

In a further embodiment of the present invention, the compound according to general formula (I) is characterized in that

R ³ denotes a C^o-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NI- C^-aliphatic residue), NKC^-aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C^OJOd^-aliphatic residue and C(=0)OH,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and unsubstituted O-C^-aliphatic residue, or denotes C ₃ . ₁₀ -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NH(d. -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, =0, O- C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)OH, C(=0)0-C ₁ . ₄ -aliphatic residue, C ₃ . ₆ -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue, and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NH(d. ₄ -aliphatic residue), N(Ci„ ₄ -aliphatic residue) ₂ , OH, =0, 0-Ci. ₄ -aliphatic residue, OCF ₃ , CF ₃ , CN, Ci- 4-aliphatic residue and C(=0)OH,

and

wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a Ci _-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NH(d. ₄ -aliphatic residue), N(Ci. ₄ -aliphatic residue) ₂ , OH, =0, O-C^-aliphatic residue, C(=0)-0-C ₁ . ₄ -aliphatic residue, 0CF ₃ , CF ₃ , CN, C _1-4 - aliphatic residue and C(=0)OH, on the condition that if R ³ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , an NH(d.4-aliphatic residue), N(C _1- -aliphatic residue) ₂ , OH, 0-Ci. ₄ -aliphatic residue, OCF ₃ , CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , C(=0)OC ₂ H ₅ , C ₃ . ₆ -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl,

, thiazolyl and oxazolyl,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and unsubstituted O-C^-aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NHKC^-aliphatic residue), N(Ci_ ₄ -aliphatic residue) ₂ , OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NF^C^-aliphatic residue), r^C^-aliphatic residue) ₂ , OH, =0, 0-C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, d. 4-aliphatic residue and C(=0)OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally linked, preferably in each case is linked, via a C _1- -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-d. ₄ -aliphatic residue, 0CF ₃ , CF ₃ , CN and C(=0)0H, and

R ⁴ denotes H or C^o-aliphatic residue, preferably C _-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NH(d. ₄ -aliphatic residue), N(d. -aliphatic residue) ₂ , OH, =0, 0-C _ -aliphatic residue, OCF ₃ , CF ₃ , CN, d. ₄ -aliphatic residue and C(=0)OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and unsubstituted 0-d. ₄ -aliphatic residue,

or

R ³ and R ⁴ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NH(Ci. ₄ -aliphatic residue), N(d_ ₄ -aliphatic residue) ₂ , OH, =0, 0-C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(=0)OH, C^- cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, OCF ₃ , CF ₃ and unsubstituted 0-d_ ₄ -aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 7 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NH(C _1-4 -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-C _1-4 - aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue and C(=0)OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl, pyridyl or thienyl, wherein the aryl or heteroaryl residues fused in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NH(d_ ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , liphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with a C ₃ _ 1 ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, wherein the C ₃ .io-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , Nf- C^-aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , =0, OH, 0-d_ ₄ -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , C(=0)OC ₂ H ₅ , C ₃ _e-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the d_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and unsubstituted 0-C _1-4 -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NH(d. ₄ -aliphatic residue), N(d- ₄ -aliphatic residue) ₂ , OH, 0-d_ ₄ -aliphatic residue, OCF ₃ , CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , and

wherein the C^e-cycloaliphatic residue and the 3 to 7 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, NH ₂ , NH(d. ₄ -aliphatic residue), N(d. ₄ -aliphatic residue) ₂ , OH, =0, 0-C _1-4 - aliphatic residue, OCF ₃ , CF ₃ , CN, d. ₄ -aliphatic residue and C(=0)OH.

In a further preferred embodiment of the compound according to general formula (I),

R ³ represents the partial structure (T2),

- -(CR ^3a R ^3b ) R ^3c

c ⁰

(T2),

wherein

o denotes 0, 1 , 2 or 3,

R ^3a and R ^3b each independently of one another represent H, F, CI, Br, I, O-C^-aliphatic residue or d-

4-aliphatic residue or together denote =0, and

R ^3c denotes C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, =0, 0-d. ₄ -aliphatic residue, CF ₃ and

C _1-4 -aliphatic residue, wherein the C - -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and 0-C-i. ₄ -aliphatic residue,

or denotes C ₃ . ₀ -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, O-C^-aliphatic residue, CF ₃ and C^-aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and unsubstituted 0-C _1-4 -aliphatic residue,

or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, O-C aliphatic residue, OCF ₃ , CF ₃ , CN, C^-aliphatic residue, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , C(=0)OC ₂ H ₅ , C ₃ . ₆ - cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,

wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0-Ci- ₄ -aliphatic residue, OCF ₃ , CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , OCH ₃ , CF ₃ and OCF ₃ , and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, O-C^-aliphatic residue, OCF ₃ , CF ₃ , d. ₄ -aliphatic residue and C(=0)-OH,

and

R ⁴ denotes H or unsubstituted C^-aliphatic residue or C^-aliphatic residue, monosubstituted with OCH ₃ ,

or

R ³ and R ⁴ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, C(=0)OH, O-C^-aliphatic residue, OCF ₃ , SCF ₃ , S-C _1-4 -aliphatic residue, CF ₃ , C^-aliphatic residue, cyclopropyl, cyclobutyl and cyclopentyl,

wherein the C _1-4 -aliphatic residue is in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, CF ₃ and O-C^-aliphatic residue,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0-C,. ₄ -aliphatic residue, OCF ₃ , SCF ₃ , S-C^-aliphatic residue, CF ₃ , Ci_ ₄ -aliphatic residue, C(=0)OH and C ₃ _6-cycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and unsubstituted 0-C-|. ₄ -aliphatic residue, and

wherein the C ₃ . ₆ -cycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, O-C^-aliphatic residue, OCF ₃ , SCF ₃ , S-C,. ₄ -aliphatic residue, CF ₃ , C,_ ₄ - aliphatic residue and C(=0)OH,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with a C ₃ . ₆ -cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cyclopentyl, or a 3 to 7 membered

heterocycloaliphatic residue, preferably oxetanyl or oxiranyl, wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, O-C^-aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN, d. ₄ -aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ .

More preferably,

R ³ represents the partial structure (T2),

wherein

0 denotes 0, 1 , 2 or 3, preferably denotes 1 or 2, more preferably denotes 1 ,

R ^3a and R ^3b each independently of one another represent H, F, CI, O-C^-aliphatic residue or C _-4 - aliphatic residue or together denote =0,

preferably each independently of one another represent H, F, O-C^-aliphatic residue or

C _1-4 -aliphatic residue or together denote =0, and

R ^3c denotes C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, =0, O-C^-aliphatic residue, CF ₃ , and Ci_ 4-aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and unsubstituted O-C^-aliphatic residue,

or denotes C ₃ . ₁₀ -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, O-C^-aliphatic residue, CF ₃ , and C ₁ _ ₄ -aliphatic residue,

wherein the Ci _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and unsubstituted O-C^-aliphatic residue,

or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, O-C^-aliphatic residue, OCF3, CF ₃ , CN, C _n-4 -aliphatic residue, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , C3- 6-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be

unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue,

C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ ,

preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-Ci. ₄ -aliphatic residue, OCF ₃ , CF ₃ , C^-aliphatic residue and C(=0) OH,

and

R ⁴ denotes H or unsubstituted C - -aliphatic residue or C^-aliphatic residue monosubstituted with OCH ₃ ,

wherein the C- -aliphatic residue is in each case preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl and tert.-butyl, more preferably selected from the group consisting of methyl and ethyl,

or

R ³ and R ⁴ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, more preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepan l, thiomorpholinyl, azepanyl, , in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, C(=0)OH, 0-C _M -aliphatic residue, OCF ₃ , CF ₃ , C _1-4 -aliphatic residue, cyclopropyl, cyclobutyl and cyclopentyl,

wherein the C^-aliphatic residue is in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, CF ₃ and unsubstituted 0-C . -aliphatic residue,

preferably is in each case unsubstituted,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , Ci-4-aliphatic residue, C(=0)OH and C3- ₆ -cycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and unsubstituted 0-C-|. ₄ -aliphatic residue, and

wherein the C ₃ . ₆ -cycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , C-^-aliphatic residue and C(=0)OH,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with a C ₃ - 6-cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cycclopentyl, or a 4 to 7 membered heterocycloaliphatic residue, preferably oxetanyl or oxiranyl, wherein the C ₃ . ₆ -cycloaliphatic residue or the 4 to 7 membered

heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, =0, OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , CN, C^-aliphatic residue, C(=0)OH, C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ .

In a further preferred embodiment of the compound according to general formula (I),

R ³ represents the partial structure (T2),

wherein

0 denotes 0, 1 , 2 or 3,

R ^3a and R ^3b each independently of one another represent H, F, CH ₃ or OCH ₃ , or together denote =0, R ^3c denotes C _-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, =0, O-C^-aliphatic residueand CF ₃ , or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, O-C^-aliphatic residue, CF ₃ and Ci_ ₄ -aliphatic residue,

or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , CN, and C _1- -aliphatic residue,

and

R ⁴ denotes H, CH ₃ , CH ₂ CH ₃ , CH ₂ CH ₂ OCH ₃ or CH ₂ CH ₂ CH ₂ OCH ₃ ,

or

R ³ and R ⁴ form together with the nitrogen atom connecting them a heteroaliphatic residue, selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroq o[1 ,2- ajpyrazinyl, dihydroindolinyl, or dihydroisoindolyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, C(=0)OH, OCH ₃ , OCH ₂ CH ₃ , OCF ₃ , SCF ₃ , CF ₃ , C(=0)CH ₃ ,

C(=0)OCH ₃ , CH ₂ CF ₃ , CH ₂ OH, CH ₂ OCH ₃ , CH ₂ CH ₂ OCH ₃ , CH ₃ , CH ₂ CH ₃ , CH ₂ CH ₂ CH ₃ , CH(CH ₃ ) ₂ and cyclopropyl.

In a particularly preferred embodiment of the present invention, the compound according to general formula (I) is characterized in that

A ¹ represents CR ⁵ , N;

A ² represents CR ⁶ , N, 0, S or NR ⁷ ;

A ³ represents CR ⁸ or N, and

n denotes 0 or 1 ,

on the condition, that

if n denotes 0, then A ² represents O, S or NR ⁷ , or

if n denotes 1 , then A ² represents CR ⁶ or N,

wherein

R ⁵ denotes F, CI, CH ₃ , OCH ₃ or CH ₂ CH ₃ ; and/or

R ⁶ denotes H; and/or

R ⁷ denotes CH ₃ , CH ₂ CH ₃ or cyclopropyl; and/or

R ⁸ denotes H;

with the proviso, that,

if n denotes 1 , then at least one of A ¹ , A ² and A ³ denotes N,

with the proviso, that

if n denotes 1 and A ³ denotes N, then A ¹ and/or A ² denotes N,

and with the proviso, that

if n denotes 1 and A ² denotes N and A ¹ denotes CR ⁵ and A ³ denotes CR ⁸ , then R ⁵ denotes F, CI,

CH ₃ , CF ₃ , CHF ₂ or CH ₂ F;

R ³ represents H or CH ₃ ; represents the partial structure (T1),

- -(CR ^{1 a} R ^b ) R ^1c

ζ (T1 ),

wherein

m denotes 1 or 2,

R ^1a and R ^1b represent H and

R ^1c denotes d_ ₄ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, O-C^-aliphatic residue, CF ₃ and C,.

4-aliphatic residue,

or denotes C ₃ . ₁₀ -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, 0-C _1-4 -aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, or wherein

m denotes 0 and

R ^1c denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , CN, d.4-aliphatic residue, C(=0)-CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ , C(=0)OC ₂ H ₅ , C ₃ . ₆ - cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,

wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , CN, C^-aliphatic residue,

C(=0)CH ₃ , C(=0)C ₂ H ₅ , C(=0)OCH ₃ and C(=0)OC ₂ H ₅ , and

wherein the C ₃ . ₆ -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C ₁ .4- aliphatic residue, OCF ₃ , CF ₃ C^-aliphatic residue and C(=0)OH;

R ² is selected from the group consisting of CH ₃ , C ₂ H ₅ , CH ₂ CH ₂ CH ₃ , CH(CH ₃ ) ₂ , CH ₂ CH ₂ CH ₂ CH ₃ , CH ₂ CH(CH ₃ ) ₂ , CH(CH ₃ )CH ₂ CH ₃ , C(CH ₃ ) ₃ , CH ₂ -cyclopropyl, OCH ₃ , OC ₂ H ₅ , OCH ₂ CH ₂ CH ₃ , OCH(CH ₃ ) ₂ , O-cyclopropyl, SCH ₃ , SC ₂ H ₅ , SCH ₂ CH ₂ CH ₃ , SCH(CH ₃ ) ₂ , S-cyclopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N(CH ₃ ) ₂ , N(CH ₃ )C ₂ H ₅ , N(CH ₃ )CH ₂ CH ₂ CH ₃ , N(CH ₃ )CH(CH ₃ ) ₂ , N(CH ₃ )-cyclopropyl, N(C ₂ H ₅ ) ₂ , N(C ₂ H ₅ )CH ₂ CH ₂ CH ₃ , N(C ₂ H ₅ )CH(CH ₃ ) ₂ , N(C ₂ H ₅ )-cyclopropyl, N- aziridinyl, N-azetidinyl, N-pyrrolidinyl, N-piperidinyl or N-morpholinyl,

in each case unsubstituted or mono- or polysubstituted with F, OH and/or OCH ₃ ;

R ³ represents the partial structure (T2)

-?-(CR ^3a R ^3b ) R ^3c

(T2),

wherein

0 denotes 0, 1 , 2 or 3,

R ^3a and R ^3b each independently of one another represent H, F, CH ₃ or OCH ₃ , or together denote =0, R ^3c denotes C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, =0, O-C^-aliphatic residue and CF ₃ , or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyranyl,

in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, 0-Ci. ₄ -aliphatic residue, CF ₃ and C^-aliphatic residue, or denotes aryl or heteroaryi, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, OH, O-C^-aliphatic residue, OCF ₃ , CF ₃ , CN, and C _-4 -aliphatic residue,

and

R ⁴ denotes H, CH ₃ , CH ₂ CH ₃ , CH ₂ CH ₂ OCH ₃ or CH ₂ CH ₂ CH ₂ OCH ₃ ,

or

R ³ and R ⁴ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl,

pyrroiidinyi, azetidinyl, oxazepanyl, tetrahydroquinolinyi, tetrahydroisoquinolin thiomorphoiinyi, azepanyl, tetrahydroimidazo[1 ,2-a]pyrazinyl, octahydropyrrolo[1 ,2-a]pyi

_ dihydroindolinyl, or dihydroisoindolyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, C(=0)OH, OCH ₃ , OCH ₂ CH ₃ , OCF ₃ , SCF ₃ , CF ₃ , C(=0)CH ₃ , C(=0)OCH ₃ , CH ₂ CF ₃ , CH ₂ OH, CH ₂ OCH ₃ , CH ₂ CH ₂ OCH ₃ , CH ₃ , CH ₂ CH ₃ , CH ₂ CH ₂ CH ₃ , CH(CH ₃ ) ₂ and cyclopropyl.

In another particularly preferred embodiment of the invention, the compound according to general formula

(I) is characterized in that

A ¹ represents CR ⁵ , N;

A ² represents CR ⁶ , N, O, S or NR ⁷ ;

A ³ represents CR ⁸ or N, and

n denotes 0 or 1 ,

on the condition, that

if n denotes 0, then A ² represents O, S or NR ⁷ , or

if n denotes 1 , then A ² represents CR ⁶ or N,

wherein

R ⁵ denotes F, CI, CH ₃ , OCH ₃ or CH ₂ CH ₃ ; and/or

R ⁶ denotes H; and/or

R ⁷ denotes CH ₃ , CH ₂ CH ₃ or cyclopropyl; and/or

R ⁸ denotes H;

with the proviso, that

iiff nn ddeennootteess 1 ' , then at least one of A ¹ , A ² and A ³ denotes N,

with the proviso, that

if n denotes 1 and A ³ denotes N, then A ¹ and/or A ² denotes N,

and with the proviso, that

if n denotes 1 and A ² denotes N and A ¹ denotes CR ⁵ and A ³ denotes CR ⁸ , then R ⁵ denotes F, CI, CH ₃ , CF ₃ , CHF ₂ or CH ₂ F; R ¹ represents phenyl or pyridyl, preferably phenyl, in each case unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, OH, OCH3, OCF ₃ , CF ₃ , and CH ₃ ,

R ² denotes CH ₂ CH ₃ , CH(CH ₃ ) ₂ , C(CH ₃ ) ₃ , cyclopropyl, cyclobutyl or cyclopentyl or tetrahydropyranyl, or

denotes S-R ⁹ or O-R ¹⁰ , wherein R ⁹ and R ¹⁰ in each case denote CH ₃ , CH ₂ CH ₃ , CH(CH ₃ ) ₂ or C(CH ₃ ) ₃ , or

denotes N(R ¹¹ R ¹² ),

wherein

R ¹¹ denotes CH ₃ , CH ₂ CH ₃ , CH(CH ₃ ) ₂ or C(CH ₃ ) ₃ ,

R ¹² denotes H, CH ₃ or CH ₂ CH ₃ ,

or

R ¹¹ and R ¹² form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted or mono- or polysubstituted with F, OH and/or OCH ₃ ;

R ³ denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyranyl,

cyclopropyimethyl, cyclobutyimethyl, cyciopentylmethyl or cyclohexylmethyl, pyrrolidin-1-ylmethyl, morpholin-1 -ylmethyl, piperazin-1 -ylmethyl, piperidin-1 -ylmethyl or tetrahydropyran-4-ylmethyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, O-C^-aliphatic residue, CF ₃ and C _-4 -aliphatic residue,

and R ⁴ denotes CH ₃ ,

or

R ³ and R ⁴ form together with the nitrogen atom connecting them heterocycloaliphatic residue,

selected from morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, in each case unsubstituted or mono- or polysubstituted with F, OH, CH ₃ and/or OCH ₃ .

Especially particularly preferred are compounds according to general formula (I) selected from the group comprising:

1 N-[(4-Chlorophenyl)-methyl]-4-ethylsulfanyl-6-methyl-2-morph olin-4-yl-pyrimidine-5-carboxylic acid amide;

2 N-[(4-Chlorophenyl)-methyl]-4,6-dimethoxy-2-morpholin-4-yl-p yrimidine-5-carboxylic acid amide;

3 N-[(4-Chlorophenyl)-methyl]-4-ethylsulfanyl-2-methyl-6-morph olin-4-yl-pyridine-3-carboxylic acid amide;

4 N-[(4-Chlorophenyl)-methyl]-2-methyl-6-morpholin-4-yl-4-prop yl-pyridine-3-carboxylic acid amide;

5 N-(4,4-Dimethyl-pentyl)-4-ethoxy-2-methyl-6-morpholin-4-yl-p yridine-3-carboxylic acid amide;

6 N-(4,4-Dimethyl-pentyl)-4-[(3R)-3-fluoro-pyrrolidin-1 -yl]-2-methyl-6-morpholin-4-yl-pyridine-3- carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-3-isopropyl-5-morpholin-4-yl-pyr azine-2-carboxylic acid amide;

N-[(4-Chlorophenyl)-methyl]-3-isopropyl-5-morpholin-4-yl- pyridine-2-carboxylic acid amide;

4-lsopropyl-2-(methyl-tetrahydro-pyran-4-yl-amino)-N-[1-[ 3-(trifluoromet yloxy)-phenyl]-ethyl]- thiazole-5-carboxylic acid amide;

4-Ethylsulfanyl-N-[(3-fluorop enyl)-met yl]-6-methyl-2-morp olin-4-yl-pyrimidine-5-carboxylic acid amide;

4-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-2-methyl-6-mo rpholin-4-yl-pyridine-3-carboxylic acid amide;

4-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-2-methyl-6-mo rpholin-4-yl-pyridine-3-carboxylic acid amide;

N-(4,4-Dimethyl-pentyl)-4-ethylsulfanyl-2-methyl-6-morpho lin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]^-et ylsulfanyl-2-methyl-6-^3R)-3-methyl-morpholin-4-yl]-pyridine -3- carboxylic acid amide;

N-(4,4-Dimethyl-pentyl)-4-ethylsulfanyl-2-methyl-6-[(3R)- 3-methyl-morpholin-4-yl]-pyridine-3- carboxylic acid amide;

N-[(4-Chlorophenyl)-methyl]-4-cyclopropyl-2-methyl-6-morp holin-4-yl-pyridine-3-carboxylic acid amide;

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-methyl-6-morp acid amide; N-[(4-Chlorophenyl)-methyl]^-ethoxy-2-methyl-6-morpholin-4-y l-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]^-dimethylamino-2-methyl-6-morpho lin-4-yl-pyridine-3-carboxylic acid amide;

N-[(4-Chlorophenyl)-methyl]-3-(1-methyl-propyl)-5-morphol in-4-yl-pyrazine-2-carboxylic acid amide; N-(2-Cyclopentyl-ethyl)-3-(1-methyl-propyl)-5-morp olin-4-yl-pyrazine-2 -carboxylic acid amide; 4-lsopropyl-2-[methyl-(tetrahydro-pyran^-yl-methyl)-amino]-N -[1 -[3-(trifluoromethylox

ethyl]-thiazole-5-carboxylic acid amide;

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-(methyl-tetrahy dro-pyran-4-yl-amino)-thiazole-5-carboxyli acid amide;

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-[methyl-(tetrah ydro-pyran-4-yl-methyl)-amino]-thiazole-5- carboxylic acid amide;

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-morpholin-4-yl- thiazole-5-carboxylic acid amide;

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-piperidin-1 -yl-thiazole-5-carboxylic acid amide;

N-(4,4-Dimethyl-pentyl)-4-isopropyl-2-piperidin-1 -yl-thiazole-5-carboxylic acid amide;

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-([1 ,4]oxazepan-4-yl)-thiazole-5-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-isopropyl-2-([1 ,4]oxazepan-4-yl)-thiazole-5-carboxylic acid amide;

N-[(3,4-Difluoro-phenyl)-methyl]-2-morpholin-4-yl-4-propy l-thiazole-5-carboxylic acid amide;

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-morpholin-4-yl- oxazole-5-carboxylic acid amide;

N-(4,4-Dimethyl-pentyl)-4-isopropyl-2-morpholin-4-yl-oxaz ole-5-carboxylic acid amide;

N-(4,4-Dimethyl-pentyl)-5-isopropyl-3-methyl-2-morpholin- 4-yl-3H-imidazole-4-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-5-isopropyl-3-methyl-2-morpholin -4-yl-3H-imidazole-4-carboxylic acid amide;

2-(Methyl-tetrahydro-pyran-4-yl-amino)-4-(trifluoromethyl )-N-[1-[3-(trifluoromethyloxy)-phenyl]-ethyl]- thiazole-5-carboxylic acid amide; 36 2-(Methyl-tetrahydro^yran-4-yl-amino)-4-(trifluoromethyl)-N- [[3-(trifluoromethy

thiazole-5-carboxylic acid amide;

37 N-[1 -(4-Chlorophenyl)-ethyl]-2-(methyl-tetrahydro-pyran-4-yl-ami no)-4-(trifluoromethyl)-thi

carboxylic acid amide;

38 N-[(4-Chlorophenyl)-methyl]-2-(methyl-tetrahydro-pyran-4-yl- amino)-4-(trifluoromethyl)-thiazole-5- carboxylic acid amide;

39 N-[(4-Chlorophenyl)-methyl]-2-[methyl-(tetrahydro-pyran-4-yl -methyl)-amino]-4-(trifluoromethyl)- thiazole-5-carboxylic acid amide;

40 2-Morpholin-4-yl-4-(trifluoromethyl)-N-[1 -[3-(trifluoromethyloxy)-phenyl]-ethyl] hiazole-5-carbo

acid amide;

41 2-Morpholin-4-yl-4-(trifluoromethyl)-N-[[3-(trifluoromethylo xy)-phenyl]-methyl]-thiazole-5-carboxylic acid amide;

42 N-[1 -(4-Chlorophenyl)-ethyl]-2-morpholin-4-yl-4-(trifluoromethyl )-thiazole-5-carboxylic acid amide;

43 N-[(4-Chlorophenyl)-methyl]-2-morpholin-4-yl-4-(trifluoromet hyl)-thiazole-5-carboxylic acid amide;

44 2-Morpholin-4-yl-4-(trifluoromethyl)-N-[1-[3-(trifluoromethy l)phenyl]-ethyl]-thiazole-5-carboxyl^ acid amide; respectively in the form of the free compounds, in the form of the salts of physiologically acceptable acids or bases and/or in the form of solvates, and/or , if applicable as racemate; as individual enantiomers, as individual diastereomers, as mixtures of enantiomers in any mixing ratio or as diastereomers in any mixing ratio.

The compounds of the general formula (I) and corresponding stereoisomers and also the respective corresponding salts and solvates are toxicologically safe and are therefore suitable as pharmaceutical active ingredients in pharmaceutical compositions.

In another aspect, the present invention therefore further relates to a pharmaceutical composition containing at least one compound according to general formula (I), in each case if appropriate in the form of one of its pure stereoisomers, in particular enantiomers or diastereomers, its racemates or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or respectively in the form of a physiologically acceptable salt, or respectively in the form of a corresponding solvate, and also if appropriate one or more pharmaceutically acceptable auxiliaries.

These pharmaceutical compositions according to the invention are suitable in particular for the modulation of KCNQ2/3 K ⁺ channels, preferably for KCNQ2/3 K ⁺ channel inhibition and/or KCNQ2/3 K ⁺ channel stimulation, i.e. they exert an agonistic or antagonistic effect.

Likewise, the pharmaceutical compositions according to the invention are preferably suitable for the prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K ⁺ channels. The pharmaceutical composition according to the invention is suitable for administration to adults and children, including toddlers and babies. The pharmaceutical composition according to the invention may be prepared as a liquid, semisolid or solid pharmaceutical form, for example in the form of injection solutions, drops, juices, syrups, sprays, suspensions, tablets, patches, capsules, plasters, suppositories, ointments, creams, lotions, gels, emulsions, aerosols or in multiparticulate form, for example in the form of pellets or granules, if appropriate pressed into tablets, decanted in capsules or suspended in a liquid, and also be administered as much.

In addition to at least one substituted compound of general formula (I), if appropriate in the form of one of its pure stereoisomers, in particular enantiomers or diastereomers, its racemate or in the form of mixtures of the stereoisomers, in particular the enantiomers or diastereomers, in any desired mixing ratio, or if appropriate in the form of a corresponding salt or respectively in the form of a corresponding solvate, the pharmaceutical composition according to the invention conventionally may contain further physiologically acceptable pharmaceutical auxiliaries which, for example, can be selected from the group consisting of excipients, fillers, solvents, diluents, surface-active substances, dyes, preservatives, blasting agents, slip additives, lubricants, aromas and binders.

The selection of the physiologically acceptable auxiliaries and also the amounts thereof to be used depend on whether the pharmaceutical composition is to be applied orally, subcutaneously, parenterally, intravenously, intraperitoneally, intradermal^, intramuscularly, intranasally, buccally, rectally or locally, for example to infections of the skin, the mucous membranes and of the eyes. Preparations in the form of tablets, dragees, capsules, granules, pellets, drops, juices and syrups are preferably suitable for oral application; solutions, suspensions, easily reconstitutable dry preparations and also sprays are preferably suitable for parenteral, topical and inhalative application. The substituted compounds according to the invention used in the pharmaceutical composition according to the invention in a repository, in a dissolved form or in a plaster, and further agents promoting skin penetration being added if appropriate, are suitable percutaneous application preparations. Orally or percutaneously applicable preparation forms can release the respective substituted compound according to the invention also in a delayed manner.

The pharmaceutical compositions according to the invention can be prepared with the aid of conventional means, devices, methods and process known in the art, such as are described for example in

..Remington's Pharmaceutical Sciences", A.R. Gennaro (Editor), 17 ^th edition, Mack Publishing Company, Easton, Pa, 1985, in particular in Part 8, Chapters 76 to 93. The corresponding description is introduced herewith by way of reference and forms part of the disclosure. The amount to be administered to the patient of the respective substituted compounds according to the invention of the above-indicated general formula (I) may vary and is for example dependent on the patient's weight or age and also on the type of application, the indication and the severity of the disorder. Conventionally, 0.001 to 100 mg/kg, preferably 0.05 to 75 mg/kg, particularly preferably 0.05 to 50 mg of at least one compound according to the invention are applied per kg of the patient's body weight.

The pharmaceutical composition according to the invention is preferably suitable for the prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K ⁺ channels. The pharmaceutical composition according to the invention is more preferably suitable for the treatment and/or prophylaxis of one or more diseases and/or disorders selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias.

The pharmaceutical composition according to the invention is suitable particularly preferably for the treatment of pain, more particularly preferably of acute pain, chronic pain, neuropathic pain, visceral pain, inflammatory pain and muscular pain, and most particularly for the treatment of neuropathic pain.

The pharmaceutical composition according to the invention is also preferably suitable for the treatment and/or prophylaxis of epilepsy.

In a further aspect of the present invention, the invention therefore relates to at least one compound according to general formula (I) and also if appropriate of one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K ⁺ channels.

Preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, especially pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia- associated dyskinesias.

Particular preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, most particularly neuropathic pain.

Particular preference is also given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of epilepsy.

In another aspect of the invention, the present invention further relates to at least one compound according to general formula (I) and also if appropriate of one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K ⁺ channels.

Preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias.

Particular preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, most particularly neuropathic pain.

Particular preference is also given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of epilepsy.

Another aspect of the present invention is a method of treatment and/or prophylaxis of disorders and/or diseases, which are mediated, at least in part, by KCNQ2/3 K ⁺ channels, in a mammal, preferably of disorders and/or diseases selected from the group consisting of pain, preferably pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias, which comprises administering an effective amount of at least one compound of general formula (I) to the mammal.

The effectiveness against pain can be shown, for example, in the Bennett or Chung model (Bennett, G.J. and Xie, Y.K., A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man, Pain 1988, 33(1 ), 87-107; Kim, S.H. and Chung, J.M., An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat, Pain 1992, 50(3), 355-363), by tail flick experiments (e.g. according to D' Amour und Smith (J. Pharm. Exp. Ther. 72, 74 79 ( 941 )) or by the formalin test (e.g. according to D. Dubuisson et al., Pain 1977, 4, 161 -174). The effectiveness against epilepsy can be demonstrated, for example, in the DBA/2 mouse model (De Sarro et al., Naunyn- Schmiedeberg's Arch. Pharmacol. 2001 , 363, 330-336).

The compounds according to the invention preferably have a EC ₅₀ value of not more than

10000 nM or not more than 8000 nM, more preferably not more than 7000 nM or not more than 6000 nM, yet more preferably not more than 5000 nM or not more than 3000 nM, even more preferably not more than 2000 nM or not more than 1000 nM, yet even more preferably not more than 800 nM or not more than 700 nM, still more preferably not more than 600 nM or not more than 500 nM, yet still more preferably not more than 400 nM or not more than 300 nM, most preferably not more than 200 nM or not more than 150 nM and especially not more than 120 nM or not more than 100 nM. Methods for determining the EC ₅₀ value are known to the person skilled in the art. The EC ₅₀ value is preferably determined by fluorimetry, particularly preferably as described below under "pharmacological experiments". The invention further provides processes for the preparation of the substituted compounds according to the invention.

The chemicals and reaction components used in the reactions and schemes described below are available commercially or in each case can be prepared by conventional methods known to the person skilled in the art.

The reactions described can each be carried out under the conventional conditions with which the person skilled in the art is familiar, for example with regard to pressure or the order in which the components are added. If appropriate, the person skilled in the art can determine the optimum procedure under the respective conditions by carrying out simple preliminary tests. The intermediate and end products obtained using the reactions described hereinbefore can each be purified and/or isolated, if desired and/or required, using conventional methods known to the person skilled in the art. Suitable purifying processes are for example extraction processes and chromatographic processes such as column chromatography or preparative chromatography. All of the process steps described below, as well as the respective purification and/or isolation of intermediate or end products, can be carried out partly or completely under an inert gas atmosphere, preferably under a nitrogen atmosphere.

If the compounds according to general formula (I) are obtained, after preparation thereof, in the form of a mixture of their stereoisomers, preferably in the form of their racemates or other mixtures of their various enantiomers and/or diastereomers, they can be separated and if appropriate isolated using conventional processes known to the person skilled in the art. Examples include chromatographic separating processes, in particular liquid chromatography processes under normal pressure or under elevated pressure, preferably MPLC and HPLC processes, and also fractional crystallisation processes. These processes allow individual enantiomers, for example diastereomeric salts formed by means of chiral stationary phase HPLC or by means of crystallisation with chiral acids, for example (+)-tartaric acid, (-)- tartaric acid or (+)-10-camphorsulphonic acid, to be separated from one another.

The various, and in particular the preferred, embodiments of the first aspect of the present invention apply in analogous manner -mutatis mutandis- to the other aspects of the present invention.

General reaction scheme I (synthesis of precursors SM01-SM08):

SM01 SM02 SM03 S 04

SM06 SM07 SM08

A plurality of syntheses of and synthesis paths to compounds of the general formulae SM01 to SM08 and structurally related precursors with a very broad substitution pattern for residues ⁵ , R ⁶ , R ⁷ , R ⁸ and R ² are known in the current specialist literature. Previously unknown intermediates of the general formulae SM01 to SM08 with similar substitution patterns for residues R ⁵ , R ⁶ , R ⁷ , R ⁸ and R ² as outlined thereafter and whose syntheses are not described in greater detail can be produced by the person skilled in the art according to these known methods or by combination of the known methods.

General reaction scheme II:

I

In staged , stage06, stage08 and stage12, chloro-heteroarenes of the general formulae IM01 , IM03, IM04 and IM07 respectively, can be transformed into the corresponding amino-heteroarenes of the general formulae IM02, IM05, IM06 and I respectively, with amines of the general formula HNR ² R ³ according to methods known to the person skilled in the art, for example by conventional or microwave heating, neat or in solution, for example in acetonitrile, dimethylformamide, dioxane, N-methyl-2- pyrrolidone or tetrahydrofuran, optionally in the presence of a suitable base, for example triethylamine, Ν,Ν-diisopropylethylamine, potassium carbonate, caesium carbonate, sodium tert-butoxide or potassium tert-butoxide, optionally by addition of a suitable coupling reagent, for example

tetrakis(triphenylphosphin)-palladium, bis(dibenzylideneacetone)-palladium(0), or

tris(dibenzylideneacetone)-dipalladium(0), optionally in presence of an additional ligand, for example (2- biphenyl)di-tert-butylphosphine or 2'-bis(diphenylphosphino)-1 ,1 '-binaphthyl.

In stage02, stage04, stage09, and stage11 , chloro-heteroarenes of the general formulae IM01 , IM02, IM04, and IM06 respectively, can be transformed into the corresponding R ² -substituted-heteroarenes of the general formulae IM03, IWI05, I 07 and I respectively, with compounds of the general formula Y-R ² , where Y denotes hydrogen, a metal or organometallic residue, for example sodium, magnesium bromide, magnesium chloride, tributyltin or boronic acid, or a residue to form an organometallic reagent, according to methods known to the person skilled in the art, for example by conventional or microwave heating, neat or in solution, for example in acetonitrile, dimethylformamide, dioxane, N-methyl-2-pyrrolidone, tetrahydrofuran, methanol or ethanol, optionally in the presence of a suitable base, for example triethylamine, Ν,Ν-diisopropylethylamine, potassium carbonate, caesium carbonate, sodium tert-butoxide or potassium tert-butoxide, optionally by addition of a suitable coupling reagent, for example

tetrakis(triphenylphosphin)-palladium, bis(dibenzylideneacetone)-palladium(0),

tris(dibenzylideneacetone)-dipalladium(0), [1 ,3-bis(diphenylphosphino)propane]-dichloronickel(ll) or iron(lll) acetylacetonate, optionally in presence of an additional ligand, for example (2-biphenyl)di-tert- butylphosphine or 2'-bis(diphenylphosphino)-1 ,1 '-binaphthyl.

In stage03, stage05, stage07 and stagelO, esters of the general formulae IM01 , IM02, I 03 and IM05, respectively, can be transformed into amides of the general formulae IM04, I 06, IM07 and I

respectively, with amines of the general formula R ¹ -C(H)(R ¹³ )-NH ₂ according to methods known to the person skilled in the art, for example by the addition of trimethyl aluminium, or by ester hydrolysis to yield the corresponding carboxylic acid followed by reaction with amines of the general formula R ¹ -C(H)(R ¹³ )- NH ₂ according to methods known to the person skilled in the art, for example using a suitable coupling reagent, for example 0-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate.

Thus obtained compounds of the general formula I can be further transformed to introduce and/or exchange one or more of the substituents R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ and R ⁸ by simple derivatization reactions known to the person skilled in the art, for example esterification, ester formation, amide formation, etherification, ether cleavage, oxidation, reduction, hydrogenation, substitution or cross-coupling reactions.

Examples

The indication„M" are indications of concentration in mol/l, "MS" means mass spectrometry, "RT" means room temperature (23 ± 7 °C), "TLC" means thin layer chromatography. Further abbreviations:

AcOH acetic acid;

d days

brine saturated aqueous sodium chloride solution

DCM dichloromethane

ether diethyl ether

EtOAc ethyl acetate

EtOH ethanol

h hour(s)

m/z mass-to-charge ratio

MeOH methanol

mm minutes

THF tetrahydrofuran

v/v volume in volume

w/w weight in weight

The yields of the compounds prepared were not optimized. All temperatures are uncorrected. All starting materials which are not explicitly described were either commercially available (the details of suppliers such as for example Acros, Avocado, Aldrich, Bachem, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, Oakwood, etc. can be found in the Symyx® Available Chemicals Database of MDL, San Ramon, US or the SciFinder® Database of the ACS, Washington DC, US, respectively, for example) or the synthesis thereof has already been described precisely in the specialist literature (experimental guidelines can be found in the Reaxys® Database of Elsevier, Amsterdam, NL or the SciFinder® Database of the ACS, Washington DC, US, respectively, for example) or can be prepared using the conventional methods known to the person skilled in the art. The mixing ratios of solvents or eluents for chromatography are specified in v/v. All the intermediate products and exemplary compounds were analytically characterised by means of ¹ H-NMR spectroscopy. In addition, mass spectrometry tests (MS, m/z for [M+H] ⁺ ) were carried out for all the exemplary compounds and selected intermediate products.

Synthesis of exemplary compounds

Synthesis of example 1 : N-[(4-Chlorophenyl)-methyl]-4-ethylsulfanyl-6-methyl-2-morph olin-4-yl- pyrimidine-5-carboxylic acid amide

a) Synthesis of 3-amino-2-(ethoxycarbonyl-carbamoyl)-but-2-enoic acid methyl ester

To a solution of 3-amino-but-2-enoic acid methyl ester (1.0 g, 8.67 mmol) in dry ether (25 ml) is added N- (oxo-methylene)-carbamic acid ethyl ester (1 g, 8.67 mmol) at 0 °C and the reaction mixture is stirred at 0-5° C for 4 h. The solid is collected by filtration, rinsed with ether and dried under reduced pressure at RT to get the 3-amino-2-(ethoxycarbonyl-carbamoyl)-but-2-enoic acid methyl ester (0.71 g, 3.08 mmol, 36%). b) Synthesis of 4-methyl-2,6-dioxo-3H-pyrimidine-5-carboxylic acid methyl ester

A mixture of 3-amino-2-(ethoxycarbonyl-carbamoyl)-but-2-enoic acid methyl ester (0.71 g, 3.08 mmol) and triethylamine (30 % aqueous solution, 0.56 ml) is stirred at 50 °C for 18 h. Another portion of triethylamine (30 % aqueous solution, 0.1 ml) is added and the reaction mixture is further at 60° C for 3 h. The reaction mixture is evaporated and then acidified with AcOH. The resulting solid is collected by filtration and dried under vacuum to get 4-methyl-2,6-dioxo-3H-pyrimidine-5-carboxylic acid methyl ester (0.33 g, 1.79 mmol, 58%), which is directly used for the next step. c) Synthesis of 2,4-dichloro-6-methyl-pyrimidine-5-carboxylic acid methyl ester

4-Methyl-2,6-dioxo-3H-pyrimidine-5-carboxylic acid methyl ester (0.64 g, 3.48 mmol) is dissolved in phosphoryl chloride (6.5 ml) and to it is added tributylamine (1.75 ml). The resulting mixture is heated at 95 °C for 3 h. Excess phosphoryl chloride is distilled of and ice-water is added to the reaction mixture and extracted with EtOAc (3 x 30 ml). The combined organic layers are washed with water (30 ml), brine (30 ml), evaporated to dryness to get the crude product, which is purified by column chromatography (silica gel, 5% EtOAc/hexane) affording 2,4-dichloro-6-methyl-pyrimidine-5-carboxylic acid methyl ester (0.45 g, 2.04 mmol, 59%). d) Synthesis of 2-chloro-4-ethylsulfanyl-6-methyl-pyrimidine-5-carboxylic acid methyl ester

To a solution of 2,4-dichloro-6-methyl-pyrimidine-5-carboxylic acid methyl ester (0.18 g, 0.82 mmol) in dimethylformamide (3.5 ml) is added potassium carbonate (0.17 g, 1.23 mmol) at RT, followed by the addition of thioethanol (0.076 ml, 1.03 mmol). The resulting mixture is stirred at RT for 2 h. After completion of reaction, the mixture is diluted with ice water and extracted with EtOAc (3 x 20 ml). The combined organic layers are washed with brine (20 ml), dried over anhydrous sodium sulfate and evaporated in vacuo to get the crude product, which is purified by column chromatography (silica gel, 5% EtOAc/hexane) to yield 2-chloro-4-ethylsulfanyl-6-methyl-pyrimidine-5-carboxylic acid methyl ester, along with other mono and bis-substituted products. No further attempt is made for purification. e) Synthesis of 4-ethylsulfanyl-6-methyl-2-morpholin-4-yl-pyrimidine-5-carbo xylic acid methyl ester

The mixture obtained from the previous step (0.16 g, ~0.65 mmol) is dissolved in acetonitrile (2.5 ml) and to it are added triethylamine (0.27 ml, 1.95 mmol) and morpholine (1 14 mg, 1 .3 mmol) and stirred at RT for 30 min. After completion of the reaction, the solvent is evaporated and the solid is taken up in ethyl acetate and washed with water. The organic layer is dried over sodium sulfate and evaporated to get the crude which is purified by column chromatography (silica gel, 10% EtOAc/hexane), affording 4- ethylsulfanyl-6-methyl-2-morpholin-4-yl-pyrimidine-5-carboxy lic acid methyl ester (0.06 g, 0.2 mmol, 31 %). f) Synthesis of 4-ethylsulfanyl-6-methyl-2-morpholin-4-yl-pyrimidine-5-carbo xylic acid

To a solution of 4-ethylsulfanyl-6-methyl-2-morpholin-4-yl-pyrimidine-5-carbo xylic acid methyl ester (0.14 g, 0.47 mmol) in dioxane (3.5 ml) is added 1 M aqueous sodium hydroxide (3.5 ml) and heated at 100 °C for 4 h. The reaction mixture is evaporated, diluted with water (10 ml) and acidified with 1 M hydrochloric acid to pH 3. The aqueous layer is extracted with EtOAc (5 x 20 ml) and washed with water (20 ml), brine (20 ml) and dried over sodium sulfate. Evaporation of the solvent affords 4-ethylsulfanyl-6-methyl-2- morpholin-4-yl-pyrimidine-5-carboxylic acid (0.09 g, 0.32 mmol, 68%). g) Synthesis of N-[(4-chlorophenyl)-methyl]-4-ethylsulfanyl-6-methyl-2-morph olin-4-yl-pyrimidine-5- carboxylic acid amide

To a stirred solution of 4-ethylsulfanyl-6-methyl-2-morpholin-4-yl-pyrimidine-5-carbo xylic acid (0.09 g, 0.32 mmol) in dichloromethane (1.5 ml) are added 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (145 mg, 0.38 mmol) and diisopropylehtylamine (0.16 ml, 0.95 mmol) at 0°C followed by the addition of 4-chlorobenzyl amine (47 mg, 0.38 mmol). The reaction mixture is stirred for 2 h at RT. After completion of the reaction, the mixture is diluted with ice water (10 ml) and extracted with DCM(3 x 20 ml). The combined organic layers are washed with water (20 ml), brine (20 ml) and dried over anhydrous sodium sulfate. Evaporation under reduced pressure affords the crude product, which is purified by column chromatography (silica gel, 10% acetone/hexane) to yield N-[(4- chlorophenyl)-methyl]-4-ethylsulfanyl-6-methyl-2-morpholin-4 -yl-pyrimidine-5-carboxylic acid amide

(example 1) (85 mg, 0.21 mmol, 66%). [M+H] ⁺ 407.1 .

Synthesis of example 2: N-[(4-Chlorophenyl)-methyl]-4,6-dimethoxy-2-morpholin-4-yl-p yrimidine-5- carboxylic acid amide

a) Synthesis of 2-chloro-4,6-dimethoxy-pyrimidine-5-carboxylic acid

2-Chloro-4,6-dimethoxy-pyrimidine (5.0 g, 28.6 mmol) is dissolved in THF (100 ml) and n-butyllithium (15% in hexane) (20.0 ml, 32.0 mmol) is added at -70 °C over a period of 30 min. The mixture is allowed to stir for 30 min at -10 "C before cooling to -70 °C and subsequent addition of solid carbon dioxide (3.78 g, 85.9 mmol). The mixture is stirred for 30 min at -70 °C and then additional 1 h at 0 °C. Water is added and the mixture washed with EtOAc (50 ml) and acidified with 2M hydrochloric acid to pH 3. The precipitate is filtered off and dried in a vacuum to yield 2-chloro-4,6-dimethoxy-pyrimidine-5-carboxylic acid (1.85 g, 8.45 mmol, 30%). b) Synthesis of 2-chloro-N-[(4-chlorophenyl)-methyl]-4,6-dimethoxy-pyrimidin e-5-carboxylic acid amide To a stirred solution of 2-chloro-4,6-dimethoxy-pyrimidine-5-carboxylic acid (0.66 g, 3.0 mmol) in THF (25 ml) are added 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.14 g, 3.0 mmol) and triethylamine (0.16 ml, 0.95 mmol) at followed by the addition of 4-chlorobenzyl amine (0.53 g, 3.75 mmol). The reaction mixture is stirred for 18 h at 55 °C. After completion of the reaction, the solvent is distilled off and the solid is taken up in EtOAc (250 ml). The organic layer is washed with water (100 ml), brine (100 ml) and dried over anhydrous sodium sulfate. Evaporation under reduced pressure affords the crude product, which is used without further purification. c) Synthesis of N-[(4-chlorophenyl)-methyl]-4,6-dimethoxy-2-rnorpholin-4-yl- pyrimidine-5-carboxylic acid amide

A mixture of 2-chloro-N-[(4-chlorophenyl)-methyl]-4,6-dimethoxy-pyrimidin e-5-carboxylic acid amide (0.51 g, 1.48 mmol), morpholine (0.16 g, 1.85 mmol) and potassium carbonate (0.26 g, 1.85 mmol) in dimethylformamide (6 ml) are heated at 90 °C for 45 min. Water is added and the mixture is extracted with EtOAc (2 x 30 ml). The combined organic layers are washed with water (100 ml), brine (100 ml) and dried over anhydrous sodium sulfate. Evaporation under reduced pressure affords the crude product, which is crystallized from EtOAc (6 ml) to yield N-[(4-chlorophenyl)-methyl]-4,6-dimethoxy-2-morpholin-4- yl-pyrimidine-5-carboxylic acid amide (example 2) (199 mg, 0.51 mmol, 34%). [M+H] ⁺ 393.1.

Synthesis of example 3: N-[(4-Chlorophenyl)-methyl]-4-ethylsulfanyl-2-methyl-6-morph olin-4-yl-pyridine- -carboxylic acid amide

a) Synthesis of 4-ethylsulfanyl-2-methyl-6-morpholin-4-yl-pyridine-3-carboxy lic acid ethyl ester

To a stirred solution of 4-chloro-2-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid ethyl ester (1.90 g, 6.69 mmol) in dimethylformamide (30 ml) are added thioethanol (7.5 ml, 100 mmol) and potassium carbonate (2.77 g, 20.1 mmol) at RT. The reaction mixture is heated at 80 °C for 20 h followed by dilution with water (30 ml) and extraction with EtOAc (3 x 40 ml). The combined organic layers are washed with brine (30 ml), dried over sodium sulfate and evaporated to dryness yielding the crude product, which is purified by column chromatography (silica gel, 15% EtOAc/hexane) to yield 4-ethylsulfanyl-2-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid ethyl ester (1.6 g, 5.16 mmol, 77%). b) Synthesis of 4-ethylsulfanyl-2-methyl-6-morpholin-4-yl-pyridine-3-carboxy lic acid

To a solution of 4-ethylsulfanyl-2-methyl-6-morpholin-4-yl-pyridine-3-carboxy lic acid ethyl ester (1.14 g, 3.68 mmol) in EtOH (10 ml) are added water (20 ml) and potassium hydroxide (2.06 g, 36.8 mmol) at RT. The reaction mixture is stirred at 100 °C for 8 h. After completion of reaction, the reaction mixture is concentrated and the residue is diluted with water (5 ml). The reaction mixture is washed with EtOAc (15 ml) and the aqueous layer is acidified with 3M hydrochloric acid to pH 3. The aqueous layer is extracted with EtOAc (3 x 40 ml) and 10% isopropanol/DCM (2 x 40 ml). The combined organic layers are dried over sodium sulfate and concentrated in vacuo to yield 4-ethylsulfanyl-2-methyl-6-morpholin-4-yl-pyridine- 3-carboxylic acid (0.7 g, 2.48 mmol, 68%), which used in to next step without any further purification. c) Synthesis of N-[(4-chlorophenyl)-methyl]-4-ethylsulfanyl-2-methyl-6-morph olin-4-yl-pyridine-3- carboxylic acid amide

To a stirred solution of 4-ethylsulfanyl-2-methyl-6-morpholin-4-yl-pyridine-3-carboxy lic acid (0.20 g, 0.71 mmol) in dichloromethane (4 ml) are added 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (323 mg, 0.85 mmol) and diisopropylehtylamine (0.50 ml, 2.84 mmol) at RT followed by the addition of 4-chlorobenzyl amine (0.12 g, 0.85 mmol). The reaction mixture is stirred for 4 h at RT. After completion of the reaction, the mixture is diluted with ice water (10 ml) and extracted with DCM (3 x 20 ml). The combined organic layers are washed with water (20 ml), brine (20 ml) and dried over anhydrous sodium sulfate. Evaporation under reduced pressure affords the crude product, which is purified by column chromatography (silica gel, 15% acetone/hexane) to yield N-[(4-chlorophenyl)-methyl]- 4-ethylsulfanyl-2-methyl-6-morpholin-4-yl-pyridine-3-carboxy lic acid amide (example 3) (0.20 g, 0.49 mmol, 69%). [M+H] ⁺ 406.1.

Synthesis of example 4: N-[(4-Chlorophenyl)-methyl]-2-methyl-6-morpholin-4-yl-4-prop yl-pyridine-3- carboxylic acid amide

a) Synthesis of 2-methyl-6-morpholin-4-yl-4-[(E)-prop-1 -enyl]-pyridine-3-carboxylic acid ethyl ester To a solution of 4-chloro-2-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid ethyl ester (0.5 g, 1.76 mmol) in toluene (25 ml) are added EtOH (2.5 ml), (1 E)-1-propenylboronic acid (0.38 g, 4.40 mmol) and cesium carbonate (2.0 g, 6.16 mmol). The reaction mixture is degassed and flushed with argon for 30 min, followed by the addition of tetrakis(triphenylphosphin)-palladium (223 mg, 0.19 mmol). The reaction mixture is stirred at 120 °C for 24 h and then filtered through a pad of celite and the filtrate is concentrated in vacuo to get the crude product, which is purified by column chromatography (silica gel, 5%

EtOAc/hexane) to afford 2-methyl-6-morpholin-4-yl-4-[(E)-prop-1 -enyl]-pyridine-3-carboxylic acid ethyl ester (0.17 g, 0.59 mmol, 33%). b) Synthesis of 2-methyl-6-morpholin-4-yl-4-propyl-pyridine-3-carboxylic acid ethyl ester

A solution of 2-methyl-6-morpholin-4-yl-4-[(E)-prop-1 -enyl]-pyridine-3-carboxylic acid ethyl ester (0.38 g, 1.3 mmol) in MeOH (12 ml) is degassed and flushed with argon for 30 min followed by the addition of 10% palladium on carbon (0.10 g). The reaction mixture is stirred under an atmosphere of hydrogen for 48 h. After completion of reaction, the reaction mixture is filtered through a pad of celite. The filtrate is concentrated in vacuo to get the crude product, which is purified by column chromatography (silica gel, 5% EtOAc/hexane) to afford 2-methyl-6-morpholin-4-yl-4-propyl-pyridine-3-carboxylic acid ethyl ester (0.3 g, 1.03 mmol, 79%). c) Synthesis of N-[(4-chlorophenyl)-methyl]-2-methyl-6-morpholin-4-yl-4-prop yl-pyridine-3-carboxylic acid amide

To a solution 4-chlorobenzyl amine (0.42 ml, 3.43 mmol) in dry toluene (6 ml) is added trimethylaluminium (2M solution in toluene) (1.7 ml, 3.43 mmol) at 0 °C. The reaction mixture is stirred at 0 °C for 1 h followed by the addition of 2-methyl-6-morpholin-4-yl-4-propyl-pyridine-3-carboxylic acid ethyl ester (0.25 g, 0.86 mmol) in dry toluene (4 ml). The reaction mixture is stirred at 120 °C for 16 h. After completion of the reaction, the mixture is poured onto water (15 ml) and extracted with EtOAc (3 x 15 ml). The combined organic layers are washed with water (15 ml) and brine (15 ml), dried over sodium sulfate and concentrated in vacuo to yield the crude product, which is purified by column chromatography (silica gel, 15% acetone/hexane) to afford N-[(4-chlorophenyl)-methyl]-2-methyl-6-morpholin-4-yl-4-prop yl-pyridine- 3-carboxylic acid amide (example 4) (0.16 g, 0.41 mmol, 48%). [M+H] ⁺ 388.2.

Synthesis of example 5: N-(4,4-Dimethyl-pentyl)-4-ethoxy-2-methyl-6-morpholin-4-yl-p yridine-3- carboxylic acid amide

a) Synthesis of 4-chloro-2-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid

A solution of 4-chloro-2-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid ethyl ester (2.0 g, 7.02 mmol) in EtOH (15 ml) is treated with a solution of lithium hydroxide (0.59 g, 24.6 mmol) in water (15 ml) for 2 h at 80 °C and then for 18 h at RT. The solvent is distilled off, water is added and the mixture is acidified with 2M hydrochloric acid to pH 2 and extracted with EtOAc (4 x 50 ml). The combined organic layers are dried over magnesium sulphate and evaporated in vacuo to 4-chloro-2-methyl-6-morpholin-4-yl-pyridine-

3- carboxylic acid (1.67 g, 6.51 mmol, 93%), which is used in the next step without further purification. b) Synthesis of 4-chloro-N-(4,4-dimethyl-pentyl)-2-methyl-6-morpholin-4-yl-p yridine-3-carboxylic acid amide

To a stirred solution of 4-chloro-2-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid (0.50 g, 1.95 mmol) in THF ( 0 ml) are added 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.74 mg, 1.95 mmol) and triethylamine (1.1 ml, 7.79 mmol) at RT followed by the addition of 4,4- dimethyl-pentan-1 -amine (0.33 g, 2.14 mmol). The reaction mixture is stirred for 18 h at RT. After completion of the reaction, the mixture is diluted with 10% ammonium chloride solution (10 ml). The organic layer is washed with saturated sodium hydrogen carbonate (20 ml), brine (20 ml) and dried over anhydrous magnesium sulfate. Evaporation under reduced pressure affords the crude product, which is purified by column chromatography (silica gel, 50% EtOAc/cyclohexane) to yield 4-chloro-N-(4,4- dimethyl-pentyl)-2-methyl-6-morpholin-4-yl-pyridine-3-carbox ylic acid amide (0.51 g, 1 .44 mmol, 74%). c) Synthesis of N-(4,4-dimethyl-pentyl)-4-ethoxy-2-methyl-6-morpholin-4-yl-p yridine-3-carboxylic acid amide

Sodium hydride (60% in mineral oil) (85 mg, 2.12 mmol) is slowly added to EtOH at RT before addition of

4- chloro-N-(4,4-dimethyl-pentyl)-2-methyl-6-morpholin-4-yl-pyr idine-3-carboxylic acid amide (0.25 g, 0.71 mmol). The mixture is heated at 100 °C for 6 h. After completion of the reaction, the mixture is poured onto water (15 ml) and extracted with EtOAc (3 x 15 ml). The combined organic layers are washed with water (15 ml) and brine (15 ml), dried over magnesium sulfate and concentrated in vacuo to yield the crude product, which is purified by column chromatography (silica gel, 50% EtOAc/cyclohexane) to afford N-(4,4-dimethyl-pentyl)-4-ethoxy-2-methyl-6-morpholin-4-yl-p yridine-3-carboxylic acid amide (example 5) (0.18 g, 0.50 mmol, 70%). [M+H] ⁺ 364.3.

Synthesis of example 6: N-(4,4-Dimethyl-pentyl)-4-[(3R)-3-fluoro-pyrrolidin-1 -yl]-2-methyl-6-morpholin- 4-yl-pyridine-3-carboxylic acid amide

A mixture of 4-chloro-N-(4,4-dimethyl-pentyl)-2-methyl-6-morpholin-4-yl-p yridine-3-carboxylic acid amide (synthesized according to the methods described in sections a) and b) of example 5) (0.27 g, 0.76 mmol), (R)-3-fluoropyrrolidine hydrochloride (0.19 g, 1.53 mmol) and diisopropylethylamine (0.39 ml, 2.29 mmol) in 1-methyl-2-pyrrolidone (2.5 ml) is heated at 160 °C for 4 h. After completion of the reaction, the mixture is diluted with EtOAc and washed with 2M aqueous sodium hydroxide (15 ml), water (2 x 15 ml) and brine (15 ml), dried over magnesium sulfate and concentrated in vacuo to yield the crude product, which is purified by column chromatography (silica gel, 10% cyclohexane/EtOAc) to afford N-(4,4- dimethyl-pentyl)-4-[(3R)-3-fluoro-pyrrolidin-1 -yl]-2-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide (example 6) (0.13 g, 0.32 mmol, 42%). [M+H] ⁺ 407.3.

Synthesis of example 7: N-[(4-Chlorophenyl)-methyl]-3-isopropyl-5-morpholin-4-yl-pyr azine-2-carboxylic acid amide

a) Synthesis of 3,5-dichloro-pyrazine-2-carboxylic acid methyl ester

To a solution of 3,5-dichloro-pyrazine-2-carboxylic acid (0.50 g, 2.60 mmol) in dimethylformamide (8 ml) is added potassium carbonate (0.54 g, 3.90 mmol) at RT followed by the addition of methyl iodide (0.8 ml, 13.0 mmol). The resulting mixture is stirred at RT for 1 h. After completion of the reaction, the mixture is diluted with water (15 ml) and extracted with EtOAc (3 x 20 ml). The combined organic layers are washed with water (20 ml), brine (20 ml), dried over anhydrous sodium sulfate and evaporated in vacuo to get 3,5- dichloro-pyrazine-2-carboxylic acid methyl ester (0.45 g, 2.18 mmol, 84%), which is used in the next step without further purification. b) Synthesis of 3-chloro-5-morpholin-4-yl-pyrazine-2-carboxylic acid methyl ester

To a solution of 3,5-dichloro-pyrazine-2-carboxylic acid methyl ester (1.20 g, 5.82 mmol) in

dimethylformamide (12 ml) is added potassium carbonate (0.96 g, 6.98 mmol) at RT followed by the addition of morpholine (0.5 ml, 5.82 mmol). The resulting mixture is stirred at RT for 3 h. After completion of the reaction, the mixture is diluted with water (20 ml) and extracted with EtOAc (3 x 30 ml). The combined organic layers are washed with water (30 ml), brine (30 ml), dried over anhydrous sodium sulfate and evaporated in vacuo to get the crude product, which is purified by column chromatography (silica gel, 10% acetone/hexane) to yield 3-chloro-5-morpholin-4-yl-pyrazine-2-carboxylic acid methyl ester (1.10 g, 4.28 mmol, 73%). c) Synthesis of 3-isopropenyl-5-morpholin-4-yl-pyrazine-2-carboxylic acid methyl ester To a solution of 3-chloro-5-morpholin-4-yl-pyrazine-2-carboxylic acid methyl ester (0.50 g, 1.94 mmol) in 1 ,4-dioxane (10 ml) is added tributyl-isopropenyl stannane (1.37 g, 4.13 mmol) at RT. The resulting mixture is degassed and flushed with argon for 30 min followed by the addition of

bis(triphenylphosphine)palladiumchloride (0.20 g, 0.29 mmol). The reaction mixture is heated at 1 10 °C for 16 h. After completion of the reaction, the solvent is distilled off and the crude product is purified by column chromatography (5% potassium fluoride/silica gel, 30% acetone/hexane) to yield 3-isopropenyl-5- morpholin-4-yl-pyrazine-2-carboxylic acid methyl ester (0.32 g, 1.22 mmol, 62%). d) Synthesis of 3-isopropyl-5-morpholin-4-yl-pyrazine-2-carboxylic acid methyl ester

To a solution of 3-isopropenyl-5-morpholin-4-yl-pyrazine-2-carboxylic acid methyl ester (0.32 g, 1.22 mmol) in EtOAc (8 ml) is added 20% palladium(ll) hydroxide (0.10 g) at RT. The resulting mixture is stirred at RT for 16 h under an atmosphere of hydrogen. After completion of the reaction, the catalyst is filtered off and washed with EtOAc. The filtrate is concentrated to yield 3-isopropyl-5-morpholin-4-yl- pyrazine-2-carboxylic acid methyl ester (0.31 g, 1.17 mmol, 95%), which is used in the next step without further purification. e) Synthesis of N-[(4-Chlorophenyl)-methyl]-3-isopropyl-5-morpholin-4-yl-pyr azine-2-carboxylic acid amide

To a solution 4-chlorobenzyl amine (0.57 ml, 4.68 mmol) in dry toluene (5 ml) is added trimethylaluminium (2M solution in toluene) (2.3 ml, 4.68 mmol) at 0 °C. The reaction mixture is stirred at 0 °C for 45 min followed by the addition of 3-isopropyl-5-morpholin-4-yl-pyrazine-2-carboxylic acid methyl ester (0.31 g, 1.17 mmol) in dry toluene (3 ml). The reaction mixture is stirred at 1 10 °C for 1.5 h. After completion of the reaction, the mixture is poured onto saturated ammonium chloride solution (15 ml) and extracted with EtOAc (3 x 15 ml). The combined organic layers are washed with water (15 ml) and brine (15 ml), dried over sodium sulfate and concentrated in vacuo to yield the crude product, which is purified by column chromatography (silica gel, 15% acetone/hexane) to afford N-[(4-Chlorophenyl)-methyl]-3-isopropyl-5- morpholin-4-yl-pyrazine-2-carboxylic acid amide (example 7) (0.27 g, 0.72 mmol, 61 %). [M+H] ⁺ 375.2.

Synthesis of example 8: N-[(4-Chlorophenyl)-methyl]-3-isopropyl-5-morpholin-4-yl-pyr idine-2-carboxylic acid amide

a) Synthesis of 5-morpholin-4-yl-3-nitro-pyridine-2-carbonitrile

5-Bromo-3-nitro-pyridine-2-carbonitrile (4.0 g, 17.5 mmol, 1 eq.) is dissolved in dimethylsulfoxid (25 ml) and morpholine (3.79 ml, 43.6 mmol) is added. The reaction mixture is stirred at RT for 5 h. After completion of reaction, the mixture is poured onto water (50 ml), extracted with EtOAc (2 x 75 ml) and the combined organic layers are dried over sodium sulfate, concentrated in vacuo and purified by column chromatography (silica gel, 25% EtOAc/hexane) affording 5-morpholin-4-yl-3-nitro-pyridine-2-carbonitrile (2.8 g, 1 1.9 mmol, 68%). b) Synthesis of 3-methoxy-5-morpholin-4-yl-pyridine-2-carbonitrile

5-Morpholin- -yl-3-nitro-pyridine-2-carbonitrile (2.8 g, 11.9 mmol) is dissolved in methanol (40 ml) and a solution of solution of sodium methoxide (0.97 g, 17.9 mmol) in MeOH (20 ml) is added. The reaction mixture is heated at 75 °C for 16 h. MeOH is distilled off and the crude product is taken up in water and extracted with EtOAc (3 x 40 ml). The combined organic layers are dried over sodium sulfate, concentrated in vacuo to afford 3-methoxy-5-morpholin-4-yl-pyridine-2-carbonitrile (2.1 g, 9.58 mmol, 83%). c) Synthesis of 3-hydroxy-5-morpholin-4-yl-pyridine-2-carbonitrile

3-Methoxy-5-morpholin-4-yl-pyridine-2-carbonitrile (2.5 g, 1 1 .41 mmol, 1 eq.) is dissolved in

dimethylformamide (40 ml) and thioethanol (6.8 ml, 91.3 mmol) and potassium carbonate (6.3 g, 45.6 mmol) are added subsequently. The resulting mixture is heated at 90 °C for 16 h. The reaction mixture is diluted with water (40 ml) and the solution is acidified with 2M hydrochloric acid at 0 °C. The solid precipitate thus obtained is filtered and dried. The crude product (2.7 g) is used in the next step without further purification. d) Synthesis of trifluoro-methanesulfonic acid (2-cyano-5-morpholin-4-yl-pyridin-3-yl) ester

To a solution of 3-hydroxy-5-morpholin-4-yl-pyridine-2-carbonitrile (2.7 g, -13.1 mmol) in DCM (30 ml) are added pyridine (1.5 ml, 19.7 mmol), trifluoromethanesulfonic anhydride (2.9 ml, 19.7 mmol) at 0 °C subsequently. The reaction mixture is warmed to RT and stirred for 3 h. The mixture is poured onto water and extracted with DCM (3 x 30 ml). The combined organic layers are washed with brine (30 ml), dried over sodium sulfate and concentrated in vacuo to get the crude product, which is purified by column chromatography (silica gel, 30% EtOAc/hexane) affording trifluoro-methanesulfonic acid (2-cyano-5- morpholin-4-yl-pyridin-3-yl) ester (1.8 g, 5.35 mmol, 47%, 2 steps). e) Synthesis of 3-isopropenyl-5-morpholin-4-yl-pyridine-2-carbonitrile

To a solution of trifluoro-methanesulfonic acid (2-cyano-5-morpholin-4-yl-pyridin-3-yl) ester (1.0 g, 2.96 mmol) in 1-methyl-2-pyrrolidone (20 ml) are added lithium chloride (0.38 g, 8.88 mmol), triphenylarsine (72 mg,0.24 mmol) and the mixture is degassed and flushed with argon for 30 min before the addition of tris(dibenzylideneacetone)-dipalladium(0) (62 mg, 0.03 mmol) and copper(l) iodide (28 mg, 0.15 mmol). The mixture is stirred at RT 10 min and tributyl-isopropenyl stannane (1.28 g, 3.55 mmol) is added. The reaction mixture is heated at 120 °C for 16 h. After completion of the reaction, saturated potassium fluoride solution (50 ml) is added and stirring is continued for 30 min. The mixture is extracted with EtOAc (3 x 40 ml) and the combined organic layers are washed with brine (40 ml) and water (40 ml), dried over sodium sulfate and evaporated to dryness to get the crude product, which is purified by column chromatography (10% potassium fluoride/silica gel, 50% EtOAc/hexane) affording 3-isopropenyl-5- morpholin-4-yl-pyridine-2-carbonitrile (0.37 g, 1.61 mmol, 54%). f) Synthesis of 3-isopropyl-5-morpholin-4-yl-pyridine-2-carbonitrile

3-lsopropenyl-5-morpholin-4-yl-pyridine-2-carbonitrile (0.37 g, 1.61 mmol) is dissolved in EtOH (15 ml) and 10% palladium on carbon (85 mg) is added. The mixture is stirred under an atmosphere of hydrogen for 2 h. After completion of the reaction, the mixture is filtered through a pad of celite and concentrated in vacuo yielding 3-isopropyl-5-morpholin-4-yl-pyridine-2-carbonitrile (0.36 g, 1 .60 mmol, 54%), which is used in the next step without further purification. g) Synthesis of 3-isopropyl-5-morpholin-4-yl-pyridine-2-carboxylic acid

To a solution of yielding 3-isopropyl-5-morpholin-4-yl-pyridine-2-carbonitrile (0.36 g, 1.56 mmol) in EtOH (6 ml) is added a 4M aqueous solution of sodium hydroxide (6 ml). The solution is herated at 1 10 °C for 16 h and then filtered. The filtrate is concentrated and acidified with 2M hydrochloric acid to pH 3. The aqueous layer is extracted with 10% MeOH/DCM, dried over sodium sulfate and evaporated in vacuo affording 3-isopropyl-5-morpholin-4-yl-pyridine-2-carboxylic acid (0.27 g, 1 .08 mmol, 69%). h) Synthesis of N-[(4-chlorophenyl)-methyl]-3-isopropyl-5-morpholin-4-yl-pyr idine-2-carboxylic acid amide To a stirred solution of 3-isopropyl-5-morpholin-4-yl-pyridine-2-carboxylic acid (0.10 g, 0.39 mmol) in DCM (5 ml) are added 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (176 mg, 0.47 mmol) and diisopropylehtylamine (0.27 ml, 1.55 mmol) at 0 °C followed by the addition of 4-chlorobenzyl amine (0.14 ml, 0.47 mmol). The reaction mixture is stirred for 2 h at RT. After completion of the reaction, the mixture is diluted with ice water (10 ml) and extracted with DCM (3 x 20 ml). The combined organic layers are washed with water (20 ml), brine (20 ml) and dried over anhydrous sodium sulfate. Evaporation under reduced pressure affords the crude product, which is purified by column chromatography (silica gel, 10% acetone/hexane) to yield N-[(4-chlorophenyl)-methyl]-3-isopropyl-5- morpholin-4-yl-pyridine-2-carboxylic acid amide (example 8) (0.07 g, 0.19 mmol, 50%). [M+H] ⁺ 374.2.

Synthesis of example 9: 4-lsopropyl-2-(methyl-tetrahydro-pyran-4-yl-amino)-N-[1-[3-( trifluoromethyloxy)- ide

a) Synthesis of 2-bromo-4-methyl-3-oxo-pentanoic acid ethyl ester

To a stirred mixture of 4-methyl-3-oxo-pentanoic acid ethyl ester (5.0 g, 31.5 mmol) in carbon

tetrachloride/water (1 :1 ) (30 ml) is added a solution of bromine (1.61 ml, 31.5 mmol) in carbon tetrachloride (15 ml) at 0 °C over a period of 1 h and the resulting reaction mixture is stirred at 0 °C for 1 h. After completion of the reaction, the organic layer is washed with water (100 ml), brine (50 ml), dried over sodium sulfate and evaporated in vacuo to yield 2-bromo-4-methyl-3-oxo-pentanoic acid ethyl ester (6.7 g, 28.37 mmol, 90%). b) Synthesis of 2-amino-4-isopropyl-thiazole-5-carboxylic acid ethyl ester

To a solution of 2-bromo-4-methyl-3-oxo-pentanoic acid ethyl ester (6.7 g, 28.4 mmol) in EtOH (25 ml) is added thiourea (2.15 g, 28.4 mmol) at RT and the reaction mixture is refluxed at 100 °C for 1 h. After completion of the reaction, the mixture is poured onto ice water (100 ml) and neutralized with 18 ammonia solution and extracted with EtOAc (3 x 100 ml). The combined organic layers are washed with water (100 ml), brine (50 ml), dried over sodium sulfate and concentrated in vacuo. The residue obtained is purified by column chromatography (silica gel, 20% EtOAc/hexane) affording 2-amino-4-isopropyl- thiazole-5-carboxylic acid ethyl ester (4.7 g, 21 .9 mmol, 77%). c) Synthesis of 2-bromo-4-isopropyl-thiazole-5-carboxylic acid ethyl ester

A slurry of 2-amino-4-isopropyl-thiazole-5-carboxylic acid ethyl ester (4.65 g, 21.7 mmol) and sodium bromide (4.46 g, 43.4 mmol) in water (30 ml) is added to a stirred solution of copper(ll) sulfate pentahydrate (6.50 g, 26.0 mmol) and sulfuric acid (70 ml) at -10 °C. A solution of sodium nitrite (3.29 g, 47.7) in water (10 ml) is added to the reaction mixture over a period of 30 min and the reaction mixture is warmed to 10 °C over a period of 1 h. After completion of the reaction, the mixture is extracted with ether (200 ml). The organic layer is washed with water (100 ml), brine (50 ml), dried over sodium sulfate and evaporated to yield 2-bromo-4-isopropyl-thiazole-5-carboxylic acid ethyl ester (3.5 g, 12.6 mmol, 58%). d) Synthesis of 4-isopropyl-2-(methyl-tetrahydro-pyran-4-yl-amino)-thiazole- 5-carboxylic acid ethyl ester To a solution of 2-bromo-4-isopropyl-thiazole-5-carboxylic acid ethyl ester (0.50 g, 1.80 mmol) in 1 - methyl-2-pyrrolidone (10 ml) are added potassium carbonate (0.37 g, 2.70 mmol) and N- methyltetrahydro-2H-pyran-4-amine (0.62 g, 5.40 mmol) at RT and the reaction mixture is heated at 150 °C for 16 h. After completion of the reaction, the mixture is diluted with methyl tert-butyl ether (20 ml) and washed with water (3 x 20 ml) and brine (3 x 20 ml). The organic layer is dried over anhydrous sodium sulfate and evaporated to get the crude product, which is purified by column chromatography (silica gel, 10% EtOAc/hexane) to yield 4-isopropyl-2-(methyl-tetrahydro-pyran-4-yl-amino)-thiazole- 5-carboxylic acid ethyl ester (0.56 g, 1.92 mmol, 99%). e) Synthesis of 4-isopropyl-2-(methyl-tetrahydro-pyran-4-yl-amino)-thiazole- 5-carboxylic acid

To a solution of 4-isopropyl-2-(methyl-tetrahydro-pyran-4-yl-amino)-thiazole- 5-carboxylic acid ethyl ester (0.60 g, 1.92 mmol) in EtOH (1.5 ml) is added a solution of potassium hydroxide (0.27 g, 4.81 mmol) in water (1 ml) at RT and the reaction mixture is refluxed at 120 °C for 16 h. After completion of the reaction, the solvent is evaporated and the residue is diluted with water (10 ml) and acidified with 2M hydrochloric acid to pH 3. The aqueous layer is extracted with EtOAc (3 x 5 ml) followed by 10%

isopropanol/chloroform (2 x 15 ml). The combined organic layers are washed with water (20 ml), brine (20 ml), dried over sodium sulfate and concentrated in vacuo. The crude product is washed with 10% ether/pentane to yield 4-isopropyl-2-(methyl-tetrahydro-pyran-4-yl-amino)-thiazole- 5-carboxylic acid (0.40 g, 1.408 mmol, 73%). f) Synthesis of 4-isopropyl-2-(methyl-tetrahydro-pyran-4-yl-amino)-N-[1 -[3-(trifluoromethyloxy)-phenyl]- ethyl]-thiazole-5-carboxylic acid amide

To a stirred solution of 4-isopropyl-2-(methyl-tetrahydro-pyran-4-yl-amino)-thiazole- 5-carboxylic acid (0.15 g, 0.53 mmol) in dimethylformamide (3 ml) are added N-methylmorpholine (0.12 ml, 1.06 mmol), O- (benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (0.25 g, 0.79 mmol) at 0 °C. The reaction mixture is stirred at 0 °C for 5 min before 1 -[3-(trifluoromethyloxy)-phenyl]-ethyl-amine (0.13 g, 0.63 mmol) is added. The reaction mixture is then stirred at RT for 16 h. After completion of the reaction, the reaction mixture is diluted with EtOAc (10 ml). The organic layer is washed with saturated sodium hydrogen carbonate solution (15 ml), saturated ammonium chloride solution (15 ml), water (20 ml), and brine (20 ml), dried over sodium sulfate and evaporated to dryness to get the crude product, which is purified by column chromatography (silica gel, 5% acetone/ hexane) followed by crystallization from acetone/pentane affording 4-isopropyl-2-(methyl-tetrahydro-pyran-4-yl-amino)-N-[1 -[3- (trifluoromethyloxy)-phenyl]-ethyl]-thiazole-5-carboxylic acid amide (example 9) (0.15 g, 0.31 mmol, 58%). [M+H] ⁺ 472.2.

Synthesis of further examples

The synthesis of further examples was carried out according to the methods already described. Table 1 shows which compound were produced according to which method. It is evident to the person skilled in the art which educts and reagents were used in each case.

Table 1:

Preparation

MS m/z

Example Chemical name according to

[M+H] ⁺ example

4-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-methyl-2-

10 1 391 .2

morpholin-4-yl-pyrimidine-5-carboxylic acid amide

4-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-2-methyl-6-

11 3 390.2

morpholin-4-yl-pyridine-3-carboxylic acid amide

4-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-2-methyl-6-

12 3 390.2

morpholin-4-yl-pyridine-3-carboxylic acid amide

N-(4,4-Dimethyl-pentyl)-4-ethylsulfanyl-2-methyl-6-

13 3 380.4

morpholin-4-yl-pyridine-3-carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-4-ethylsulfanyl-2-methyl-

14 6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic 3 420.2

acid amide

N-(4,4-Dimethyl-pentyl)-4-ethylsulfanyl-2-methyl-6-

15 [(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic 3 394.3

acid amide

N-[(4-Chlorophenyl)-methyl]-4-cyclopropyl-2-methyl-6-

16 4 386.2

morpholin-4-yl-pyridine-3-carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-methyl-6-

17 4 388.2

morpholin-4-yl-pyridine-3-carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-4-ethoxy-2-methyl-6-

18 5 390.2

morpholin-4-yl-pyridine-3-carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-4-dimethylamino-2-

19 methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid 6 389.2

amide

N-[(4-Chlorophenyl)-methyl]-3-(1-methyl-propyl)-5-

20 7 389.2

morpholin-4-yl-pyrazine-2-carboxylic acid amide

N-(2-Cyclopentyl-ethyl)-3-( 1 -methyl-propyl)-5-

21 7 361.3

morpholin-4-yl-pyrazine-2-carboxylic acid amide

4-lsopropyl-2-[methyl-(tetrahydro-pyran-4-yl-methyl)-

22 amino]-N-[1 -[3-(trifluoromethyloxy)-phenyl]-ethyl]- 9 486.2

thiazole-5-carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-(methyl-

23 tetrahydro-pyran-4-yl-amino)-thiazole-5-carboxylic acid 9 408.2

amide N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-[methyl- (tetrahydro-pyran-4-yl-methyl)-amino]-thiazole-5- 9 422.2 carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-morpholin-4-

9 380.1 yl-thiazole-5-carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-piperidin-1 -

9 378.1 yl-thiazole-5-carboxylic acid amide

N-(4,4-Dimethyl-pentyl)-4-isopropyl-2-piperidin-1 -yl-

9 352.2 thiazole-5-carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-

9 394.2 ([1 ,4]oxazepan-4-yl)-thiazole-5-carboxylic acid amide

N-(4,4-Dimethyl-pentyl)-4-isopropyl-2-([1 ,4]oxazepan-

9 378.1 4-yl)-thiazole-5-carboxylic acid amide

N-[(3,4-Difluoro-phenyl)-methyl]-2-morpholin-4-yl-4-

9 382.1 propyl-thiazole-5-carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-morpholin-4-

9 364.2 yl-oxazole-5-carboxylic acid amide

N-(4,4-Dimethyl-pentyl)-4-isopropyl-2-morpholin-4-yl-

9 338.2 oxazole-5-carboxylic acid amide

N-(4,4-Dimethyl-pentyl)-5-isopropyl-3-methyl-2-

9 351 .3 morpholin-4-yl-3H-imidazole-4-carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-5-isopropyl-3-methyl-2-

9 377.1 morpholin-4-yl-3H-imidazole-4-carboxylic acid amide

2-(Methyl-tetrahydro-pyran-4-yl-amino)-4- (trifluoromethyl)-N-[1 -[3-(trifluoromethyloxy)-phenyl]- 9 498.1 ethyl]-thiazole-5-carboxylic acid amide

2-(Methyl-tetrahydro-pyran-4-yl-amino)-4- (trifluoromethyl)-N-[[3-(trifluoromethyloxy)-phenyl]- 9 484.1 methyl]-thiazole-5-carboxylic acid amide

N-[1 -(4-Chlorophenyl)-ethyl]-2-(methyl-tetrahydro- pyran-4-yl-amino)-4-(trifluoromethyl)-thiazole-5- 9 448.1 carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-2-(methyl-tetrahydro- pyran-4-yl-amino)-4-(trifluoromethyl)-thiazole-5- 9 434.1 carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-2-[methyl-(tetrahydro- pyran-4-yl-methyl)-amino]-4-(trifluoromethyl)-thiazole- 9 448.1 5-carboxylic acid amide

2-Morpholin-4-yl-4-(trifluoromethyl)-N-[1 -[3- (trifluoromethyloxy)-phenyl]-ethyl]-thiazole-5-carboxylic 9 470.1 acid amide

2-Morpholin-4-yl-4-(trifluoromethyl)-N-[[3- (trifluoromethyloxy)-phenyl]-methyl]-thiazole-5- 9 456.1 carboxylic acid amide

N-[1 -(4-Chlorophenyl)-ethyl]-2-morpholin-4-yl-4-

9 420.1 (trifluoromethyl)-thiazole-5-carboxylic acid amide

N-[(4-Chlorophenyl)-methyl]-2-morpholin-4-yl-4-

9 406.0 (trifluoromethyl)-thiazole-5-carboxylic acid amide

2-Morpholin-4-yl-4-(trifluoromethyl)-N-[1 -[3- (trifluoromethyl)phenyl]-ethyl]-thiazole-5-carboxylic 9 454.1 acid amide Pharmacological experiments

Method I. Fluorescence assay using a voltage sensitive dye (fluorimetry)

Human CHO-K1 cells expressing KCNQ2/3 channels are cultivated adherently at 37°C, 5% C0 ₂ and 95% humidity in cell culture bottles (e.g. 80 cm ² TC flasks, Nunc) with DMEM-high glucose (Sigma Aldrich, D7777) including 10% FCS (PAN Biotech, e.g. 3302-P270521 ) or alternatively MEM Alpha Medium (1 x, liquid, Invitrogen, #22571 ), 10% fetal calf serum (FCS) (Invitrogen, #10270-106, heat-inactivated) and the necessary selection antibiotics.

Before being sown out for the measurements, the cells are washed with 1 x DPBS buffer Ca ²⁺ /Mg ²⁺ -free (e.g. Invitrogen, #14190-094) and detached from the bottom of the culture vessel by using Accutase (PAA Laboratories, #L11 -007) (incubation with Accutase for 15 min at 37°C). The cell number is determined using a CASY™ cell counter (TCC, Scharfe System). Depending on the optimal density for each individual cell line, 20,000-30,000 cells/well/100 μΙ are seeded onto 96-well Corning™ CellBIND™ assay plates (Flat Clear Bottom Black Polystyrene Microplates, #3340). Freshly seeded cells are then left to settle for one hour at room temperature, followed by incubation for 24 hours at 37°C, 5% C0 ₂ and 95% humidity.

The voltage-sensitive fluorescent dye from the Membrane Potential Assay Kit (Red™ Bulk format part R8123 for FLIPR, MDS Analytical Technologies™) is prepared by dissolving the contents of one vessel Membrane Potential Assay Kit Red Component A in 200 ml of extracellular buffer (ES buffer, 120 mM NaCI, 1 mM KCI, 10 mM HEPES, 2 mM CaCI ₂ , 2 mM MgCI ₂ , 10 mM glucose; pH 7.4). After removal of the nutrient medium, the cells are washed once with 200 μΙ of ES buffer, then loaded for 45 min at room temperature in 100 μΙ of dye solution in the dark.

Fluorescence measurements are carried out in a BMG Labtech FLUOstar™, BMG Labtech NOVOstar™ or BMG Labtech POLARstar™ instrument (525 nm excitation, 560 nm emission, Bottom Read mode). After incubation with the dye, 50 μΙ of the test substances in the desired concentrations, or 50 μΙ of ES buffer for control purposes, are applied to the wells of the assay plate and incubated for 30 min at room temperature while being shielded from light. The fluorescence intensity of the dye is then measured for 5 min and the fluorescence value of each well is thus determined at a given, constant time. 15 μΙ of a KCI solution are then added to each well (final concentration of potassium ions 92 mM). The change in fluorescence intensity is subsequently monitored until all the relevant values have been obtained (mainly 5-30 min). At a given time post KCI application, a fluorescence value F ₂ is determined, in this case at the time of the fluorescence peak.

For calculation, the fluorescence intensity F ₂ is corrected for the fluorescence intensity F-, , and the activity (AF/F) of the target compound on the potassium channel is determined as follows: In order to determine whether a substance has agonistic activity, - ^F can be related to if ^J ) ^k of control wells. ( ^J ) ^k is determined by adding to the well only the buffer solution instead of the test substance, determining the value Fi _K of the fluorescence intensity, adding the potassium ions as described above, and measuring a value F _2K of the fluorescence intensity. F _2K and F _1K are then calculated as follows:

A substance has an agonistic activity on the potassium channel if - ^F is greater than if ^J ) ^k :

AF (AF)

Independently of the comparison of - ^F with if] ^Jk it is possible to conclude that a target compound has

AF_

agonistic activity if ^F increases dose dependency.

Calculations of EC ₅₀ and IC ₅₀ values are carried out with the aid of ^' Prism v4.0 ^' software (GraphPad Software™).

Method II. Low-intensity tail flick test (rat)

In the low-intensity tail flick test, the determination of the antinociceptive effect of the compounds according to the invention towards an acute noxious thermal stimulus is carried out by measuring the withdrawal reflex of the rat tail (tail flick) in response to a radiant heat beam (analgesia meter; model 201 1 of the company Rhema Labortechnik, Hofheim, Germany) according to the method described by D'Amour and Smith (J. Pharm. Exp. Ther. 72, 74 79 (1941 ). To this end, the rats were placed in a plexiglas restrainer, and a low-intensity radiant heat beam (48°C) was focused onto the dorsal surface of the tail root. The stimulus intensity was adjusted to result in a mean pre-drug control withdrawal latency of about 7 s, thus also allowing a supraspinal modulation of the spinally mediated acute nociceptive reflex. A cutoff time of 30 s was applied to avoid tissue damage. Male Sprague-Dawley rats (Janvier, Le Genest St. Isle, Frankreich) with weights of 200-250 g were used. 10 rats were used per group. Before administration of a compound according to the invention, the animals were pre-tested twice in the course of five minutes and the mean of these measurements was calculated as the pre-test mean. The antinociceptive effect was determined at 20, 40 and 60 min after peroral compound administration. The antinociceptive effect was calculated based on the increase in the tail withdrawal latency according to the following formula and is expressed as percentage of the maximum possible effect (MPE [%]):

MPE = [(T ₁ -T ₀ )/(T ₂ -To)]*100

In this, T ₀ is the control latency time before and the latency time after administration of the compound, T ₂ is the cutoff time and MPE is the maximum possible effect. Employing variant analysis (repeated measures ANOVA) allowed testing of statistically significant differences between the compounds according to the invention and the vehicle group. The significance level was set to p≤ 0.05. Pharmacological data

The pharmacological effects of the compounds according to the invention were determined as described hereinbefore (pharmacological experiments, methods I and II respectively).

The corresponding pharmacological data are summarized in Table 2.

Table 2: